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5Summary
Solar ultraviolet (UV) radiation promotes skin tumorigenesis by inducing DNA damage.
UV radiation activates cellular stress responses involving induction of transcription factor
p53 and adaptive changes in transcriptional patterns of the cells. p53 is the most often
mutated gene in human cancers, indicating its essential role in tumor suppression. Upon UV
radiation, amongst many other types of stress, p53 halts cell proliferation and induces
damage repair. However, if a particular cell has suffered from extensive, unrepairable
amount of damage, p53 launches apoptosis to prevent multiplication of the damaged
genome. If these protective cellular responses are compromized, accumulation of mutations
may lead to genomic instability and tumorigenesis.
In this study, the effects of UV radiation on p53 and cellular transcriptional changes have
been studied in human skin fibroblasts. Low doses of UV radiation induced transient cell
cycle arrest, correlating with rapid, but transient, stabilization of p53. In contrast, high doses
of UV radiation caused apoptosis with a slower, but sustained, increase in p53. This was
apparently due to a lack of induction of Mdm2, a negative regulator of p53. Regulation of
p53 target genes upon UV radiation was highly dose-dependent. PI-3-kinases, which
phosphorylate N-terminal p53 residues, were without a significant impact on UV-induced
p53 activity. Instead, C-terminal acetylation of p53 was time- and dose-dependently
regulated. Redox regulation of p53 after genotoxic insults affected its affinity towards a
subset of target genes, due to a redox state-dependent ability of p53 residue Cys277 to
contact DNA bases. p53 stabilized by proteasome inhibition was found to be
transcriptionally active, but to differ from UV-stabilized p53 in its interaction with Mdm2,
posttranslational modifications, and subnuclear localization. PI-3-kinases were found to
regulate basal expression of Mdm2, and translocation of p53 and Mdm2 into nucleoli after
inhibition of the proteasome function.
In a large scale study of transcriptional changes upon UV radiation, 460 transcripts were
found to be significantly regulated. The majority (89%) of these were repressed, supporting
the idea that UV radiation induces prominent, dose-dependent downregulation of
transcription. However, target gene-selective transrepression took also place. Dose-
dependent induction of cell cycle arrest and apoptosis by UV radiation are transcriptionally
highly distinct responses, and only 5% of the significantly regulated genes were common to
both low and high doses of radiation. The low dose induced transient changes in transcript
patterns followed by a recovery, whereas after the high dose, the changes occurred more
slowly and were persistent. A clustering analysis and functional classification of the UV-
regulated targets indicated involvement of changes in transcriptional and translational
machinery, and inflammatory, anti-proliferative, and anti-angiogenic transcripts in the
different biological responses. Several UV-regulated unknown genes were identified to be
studied further for their role in cellular stress responses.
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Abbreviations
6-4PP (6-4)-photoproduct
ARF alternative reading frame
ATM Ataxia telangiectasia mutated
ATR Ataxia telangiectasia-related
bp base pair
C carboxy
CDK cyclin-dependent kinase
CK casein kinase
CKI cyclin-dependent kinase inhibitor
CPD cyclobutane-type pyrimidine dimer
CTD C-terminal domain
DSB double strand break
ECM extracellular matrix
GGR global genomic repair
GTF general transcription factor
HAT histone acetyl-transferase
HDAC histone deacetylase
HPV human papilloma virus
KO knock-out
IR ionizing radiation
MAP mitogen-activated protein
Mdm2 Murine double minute 2
MEF mouse embryonal fibroblast
N amino
NER nucleotide excision repair
NES nuclear export signal
NLS nuclear localization signal
PI-3 phosphoinositide-3
Rb retinoblastoma
RE response element
RNAP RNA polymerase
ROS reactive oxygen species
TAD transactivation domain
TAF TBP-associated factor
TBP TATA-binding protein
TCR transcription-coupled repair
TF transcription factor
UV ultraviolet
UVB ultraviolet B radiation
UVC ultraviolet C radiation
wt wild type
XP xeroderma pigmentosum
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Introduction
Multicellular organisms have developed through disciplined control of cell division,
growth, and death, achieved by tightly regulated changes of gene expression able to adapt to
environmental challenges. The information stored in our genes lies at the heart of proper
organismal development and homeostasis, and thus has to be preserved. Several
mechanisms have evolved to maintain genomic integrity in order to ensure prevention,
removal, or destruction of undesired changes in our genetic information. These mechanisms
are not perfect, however, and errors resulting from both normal metabolic processes in the
cell and exogenous causes are sometimes left unrepaired. This imperfection guarantees
continuous evolution, but for a single cell, changes in the genetic information may pose a
threat to continued homeostasis and normal functions. At organismal level, failure of these
control mechanisms are at the cost of disease and malfunctions of organs. Maybe the most
captivating outcome from failures of this kind is cancer: the escape of cells from
surrounding restraints, resulting in cells with indefinite ability to proliferate. Ironically
enough, one of the most destructive scourge of modern man has - even though just on the
cellular level - achieved something people are so often craving for: the ability to outwit,
outplay, and outlive.
Centrally cast in the play of cancer is tumor suppressor p53. This “guardian of the
genome” is suggested to maintain genomic integrity by making decisions whether, in case
of genomic insult, the damage is reversible and the cell is allowed to survive. If yes, the
necessary actions are undertaken within the cell to repair the damage. If not, p53 serves as
the executioner triggering the destruction mechanisms which result in the death of an
irreparably damaged cell, thus preventing possible propagation of an altered genome.
p53 is challenged on a daily basis by sunlight. UV radiation, even though necessary for
the birth and maintenance of life on earth, is the most prominent physical carcinogen in our
natural environment. It possesses an ability to damage our DNA, thus inducing mutations to
our genome. p53 is able to respond to this damage in a manner still poorly understood at the
molecular level. In addition to activation of p53, other stress-responsive events take place
when cells are subjected to UV light. In this thesis, the activation of p53 and transcriptional
regulation in the cellular responses to UV radiation have been studied using human skin
fibroblasts as a model. The aim was to gain information on how cellular UV responses
normally occur, to be able to identify how they have failed in cancer.
Tumor suppressor p53 and transcriptional changes in cellular stress responses to UV radiation
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Review of the literature
REGULATION OF EUKARYOTIC GENE EXPRESSION
Human genome seems to contain approximately 30000 genes, majority of which code
for proteins holding individual characteristics (The genome international sequencing
consortium 2001, Venter et al. 2001). To achieve a proper orchestra of functional proteins
from this pool of genes within any type of a cell, at any given moment throughout
development and life of an organism, expression of genes has to be controlled in a very
detailed manner. Regulation of gene expression occurs virtually at every possible level on
the route to construct a protein according to the information on its gene: transcribing the
sequence of deoxyribonucleic acid (DNA) to a messenger ribonucleic acid (mRNA),
processing of the mRNA molecule, transportation of it to the cytoplasm, and the translation
of it on ribosomes. The main level of restriction is, according to current knowledge,
initiation of transcription.
Chromatin structure
To fit the extensive 2 m of human DNA to a cell nucleus, it is first wrapped around
histone proteins, which in their non-acetylated form have a positive charge and thus bind
DNA well. Nucleosome units of histone octamers (containing two each of H2A, H2B, H3,
and H4) wrapping 146 bp of DNA are linked by 20 bp of DNA and an additional histone
(H1), and are further coiled and folded to form chromatin fibers (Workman and Kingston
1998, Lee and Young 2000). The downside of this tight packing is the nonaccessibility of
DNA to the transcription machinery. In order to transcribe a particular sequence, positive
regulation has to occur to relieve the structural inhibition (Kornberg 1999). Nucleosomal
structure is loosened by histone acetylation to decrease the affinity of histones to DNA
(Sterner and Berger 2000). This is carried out by histone acetyltransferases (HATs) like
p300, CBP (CREB-binding protein), and p/CAF (p300/CBP-associated factor), which
render DNA accessible to other proteins, especially transcription machinery (Workman
and Kingston 1998, Chen et al. 2001). Chromatin structure is affected also by other
posttranslational modification of histones, including acetylation, phosphorylation,
methylation, and ubiquitination (van Leeuwen and Gottschling 2002). Other mechanisms
to relieve nucleosomal structures are histone octamer sliding or jumping along DNA, and
ATP-dependent histone remodelling (Workman and Kingston 1998). In addition,
availability of genomic sequences to transcriptional machinery is regulated by epigenetic
mechanisms, including silencing of genes by methylation of DNA (Jaenisch and Bird
2003).
RNA polymerase II-regulated promoters
Protein-coding genes in eukaryotic cells are transcribed by RNA polymerase II
(RNAPII). Human RNAPII machinery is composed of a 12-subunit core and general
transcription factors (GTFs; TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH), which are
necessary for the enzyme to be able to associate with a template (Woychik and Hampsey
Review of the literature
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2002). Each protein in the RNAPII machinery has a specific function to govern, for
example, interaction of the core complex with transcriptional regulators, stabilization of
the complex, selection of the start site, and regulation of the elongation rate. To start
transcription, an active RNAPII complex has to form on the promoter of the gene, a
regulatory DNA region upstream (5’) of the protein coding sequence. A promoter consists
of a core promoter, which binds the RNAPII complex, and gene-specific transcriptional
regulator-binding sites. The core promoter includes transcriptional start site and often a
TATA box 25-30 bp upstream of the start site (Lee and Young 2000). When exposed, the
TATA box is recognized by TATA-binding protein (TBP), a subunit of TFIID, which
allows sequential docking of the RNAPII complex on the promoter and thus eventually
leads to initiation of transcription (Pugh 2000).
Although the complex of RNAPII and GTFs is sufficient to drive basal gene
transcription in vitro, numerous coregulatory proteins are required for efficient
transcription in vivo (Woychik and Hampsey 2002). An orchestra of additional
transcription factors regulates a given promoter by binding to it and either promoting or
inhibiting the formation of an active RNAPII complex. Transcription factors also recruit or
inhibit histone-modifying complexes. Expression of a particular gene at a given moment
depends on the sum of these different modulatory events (Figure 1). Central to this
regulation is the composition and context of the promoter: its transcription factor-binding
sites, arrangement of these sites relative to each other influencing protein-protein
interactions, and addition of architectural proteins (Lee and Young 2000, Gill 2001). Also
other regulatory DNA elements, including enhancers and silencers located either upstream
or downstream and up to 85 kb away from the start site, can influence the expression of a
gene in trans through the regulatory factors they bind (Lee and Young 2000).
Figure 1. A model of eukaryotic RNAPII transcription initiation complex. RNAPII requires general
transcription factors (TFII) to associate with template DNA and to become active. Histone acetyl-transferases
(HAT) are needed to acetylate nucleosomal histones (sylinders) to relieve chromatin structure, and to
acetylate several transcription associatory factors. Sequence-specific transcriptional activators (octagons) and
repressors (crosses) either promote or inhibit the formation of an active transcription initiation complex. In
addition, several structural proteins are required to obtain a favourable local structure on DNA through e.g.
DNA bending (triangles). Modified from Carey 1998, Fry and Peterson 2001.
Tumor suppressor p53 and transcriptional changes in cellular stress responses to UV radiation
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Transcription factors
The normal and adaptive gene expression responses are mediated by specific
transcription factors, the regulation of which forms basis to control gene expression.  The
set of active transcription factors at a given moment in any cell varies depending on e.g.
cell type, state of differentiation, environmental signals, and stress (Fry and Farnham
1999). Transcription factors are often latent becoming functional during a physiological
response (Kornberg 1999). Their activity can be regulated by several means, usually by
changing either protein localization, pattern of posttranslational modifications, or specific
protein-protein interactions (Kornberg 1999, Sterner and Berger 2000, Freiman and Tjian
2003). Transcriptional activators have at least two domains: one to bind DNA sequence-
specifically and one to recruit or stimulate activity of chromatin-modifying complexes or
transcription initiation apparatus (Lee and Young 2000). One activator usually regulates
several genes. Transcriptional repressors can be divided into two sub-groups: general and
gene-specific (Lee and Young 2000). The general repressors often interact with TBP
inhibiting its ability to bind to promoters, thereby hindering the formation of an active
RNAPII complex. Many gene-specific transcriptional repressors bind to transcriptional
activators inhibiting their functions, or compete with them for binding sites on the
promoters (Lee and Young 2000, Courey and Jia 2001).
Review of the literature
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MAINTENANCE OF GENOMIC INTEGRITY IN EUKARYOTES
DNA is not chemically inert, and it faces both endogenous and exogenous challenges
constantly (de Laat et al. 1999). Endogenous changes, arising from normal DNA
metabolism, are probably the greatest source of DNA errors. In DNA replication, they
occur at the rate of 1 error/1010 nucleotides synthesized; a rate which is greatly enhanced in
case of defective proofreading (Jiricny 1998). Different types of DNA lesions can be
caused by exogenous effectors, such as chemical compounds and irradiation, e.g. single
and double strand breaks by ionizing radiation (IR), inter- and intrastrand crosslinks by
chemical agents such as cytostaticum cisplatin, and certain base modifications by UV
radiation (de Boer and Hoeijmakers 2000). As a result of DNA damage, transcription and
DNA replication are hampered, and thus cell cycle arrest, cell death, or decrease in
genomic instability are induced (de Boer and Hoeijmakers 2000). At organismal level,
DNA lesions cause carcinogenesis, genetic disorders, and aging (Hanawalt 1998,
Hoeijmakers 2001). To preserve genetic information intact, DNA has to adapt to the
challenges. To achieve this, a variety of enzymatic DNA fidelity control and repair
mechanisms have evolved. Through these, DNA damage is recognized by proteins which
initiate series of events leading to elimination of the lesions and to the restoration of intact
DNA (Hanawalt 1998, Hoeijmakers 2001).
The cell cycle
Eukaryotic cells multiply in the cell cycle, which is composed of four phases (Figure 2).
In the synthesis (S) phase, the genome is copied and eventually divided between the two
daughter cells in mitosis (M). In between there are two gap periods (G1 and G2), during
which cells prepare themselves for S and M phases. When cells are not dividing, they exit
the cell cycle to stay in a quiescent state (G0). The progression through different steps in
the cell cycle is tightly regulated by fluctuating activities of protein complexes composed
of cyclins and their respective kinases (cyclin-dependent kinases; CDKs) specific for
particular phases of the cell cycle (Johnson and Walker 1999, Nurse 2000) (Figure 2). The
activity of cyclin/CDK complexes is regulated by multiple mechanisms, especially by
oscillating protein synthesis and degradation of cyclins, inhibitory phosphorylations on
CDKs, and by binding of factors of the two cyclin-kinase inhibitor (CKI) families
(Arellano and Moreno 1997). INK4 (inhibitor of cdk4/6) family consists of four members,
p16Ink4a, p15Ink4b, p18Ink4c, and p19Ink4d, which have specific activities towards inhibiting
cyclin D-associated kinase activity (Vidal and Koff 2000). Members of the Cip/Kip-family
of inhibitors, p21Cip1, p27Kip1, and p57Kip2, preferentially inhibit activity of CDK2, but bind
also CDK4-containing complexes (Johnson and Walker 1999, Vidal and Koff 2000).
Tumor suppressor p53 and transcriptional changes in cellular stress responses to UV radiation
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The initial “start” of cell proliferation is progression from G1 to S phase. During mid- to
late G1 phase, a cell monitors for growth-promoting and -inhibiting signals. Provided that
the cellular environment is favourable for proliferation, the cell decides to enter S phase by
bypassing the restriction point (R) (Figure 2). Under nonstressed circumstances, this
commitment to replicate DNA and divide is irreversible until the next G1 phase (Bartek
and Lukas 2001a). G1/S transition is controlled by the retinoblastoma (Rb) protein and its
homologs p107 and p130 (Weinberg 1995, Bartek and Lukas 2001a). Rb in its
hypophosphorylated state binds and inhibits E2F transcription factors. Phosphorylation of
Rb by cyclin/CDK complexes in late G1 releases E2F factors to drive expression of genes
necessary for G1/S transition (Weinberg 1995). Another important factor for G1/S
transition is transcription factor Myc which induces several factors promoting S phase
entry (Pelengaris et al. 2002). During the cell cycle, a cell monitors successful completion
of the previous phase before proceeding to the next one. These key transitions are often
referred to as the cell cycle checkpoints (Hartwell and Weinert 1989).
Figure 2. The cell cycle and DNA damage checkpoints. Cells multiply by dividing in the cell cycle driven by
activities of different cyclin-CDK complexes (see text for details). The integrity of DNA is monitored in
DNA damage checkpoints in late G1, late G2 and M (spindle checkpoint). R, restriction point.
Review of the literature
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DNA damage checkpoints
Integrity of DNA is monitored during the cell cycle in DNA damage checkpoints which
mostly overlap the cell cycle checkpoints (Zhou and Elledge 2000) (Figure 2). If either
replication errors or DNA damage exists, cell cycle progression is arrested and DNA repair
mechanisms are activated. The cell cycle arrest is maintained until the damage has been
repaired, after which re-entry to the cell cycle is allowed (Hartwell and Weinert 1989,
Bartek and Lukas 2001b). The main DNA damage checkpoints function in late G1 and late
G2. During mitosis, the spindle checkpoint monitors for chromosome aberrations before
chromosome segregation. In addition, an intra-S DNA damage surveillance exists to
monitor for presence of DNA damage, especially double strand breaks (DSBs). This
mechanism is often referred to as a checkpoint, but, in contrast to the other DNA damage
checkpoints, the intra-S surveillance does not have the ability to halt cell cycle progression,
only to slow it down (Bartek and Lukas 2001b).
The importance of DNA damage checkpoints is underlined by their evolutionary
conservation (Zhou and Elledge 2000). They are composed of monitoring systems
identifying DNA lesions, signal transducers communicating this information onwards, and
effectors halting the cell cycle and repairing the lesions (Zhou and Elledge 2000, Bartek
and Lukas 2001b). The upstream elements of the surveillance cascades seem to be mostly
shared by different checkpoints, but the downstream effectors and their targets vary
(Bartek and Lukas 2001b). Despite that most proteins needed for DNA repair are
identified, it is still not finally established how the different types of damage are
recognized and how the decisions on the cellular response are made (Hanawalt 1998).
The primary DNA damage sensors may include the Rad1-Rad9-Hus1 complex, Rad17,
and the phosphoinositide-3-kinase (PI-3-kinase)-related proteins ataxia telangiectasia
mutated (ATM) and ataxia telangiectasia-related (ATR) (Bartek and Lukas 2001a,b). The
choice of transducers may depend on the damage type and the primary sensors. For
example, ATM and ATR have overlapping functions, but the former is essential for IR-
induced and the latter for UV-induced phosphorylation of several G1/S checkpoint proteins
(Figure 3). First, a rapid cell cycle arrest is induced by activating the Chk1/Chk2 kinases,
which then phosphorylate the Cdc25A phosphatase (Mailand et al. 2000). This leads to
ubiquitination of Cdc25A and its rapid degradation by the proteasome, rendering the
respective cyclinE/Cdk2 complex inactive through an inhibitory phosphorylation, and
inhibiting entry into the S phase (Bartek and Lukas 2001a). Later, the same kinases
function to maintain the cell cycle arrest through induction of tumor suppressor p53, while
cyclin D is also downregulated, resulting in inhibition of the cyclinE/Cdk2 complexes by
increased interaction with the CKI protein p21Cip1 (Bartek and Lukas 2001a, Agami and
Bernards 2002). ATM/ATR also regulate G2/M checkpoint via analogous cascades and the
intra-S checkpoint by targeting several DNA repair-associated proteins, such as Brca1
(breast cancer 1) and NBS1 (Nijmegen Breakage Syndrome 1) (Abraham 2001, Bartek and
Lukas 2001b, Pietenpol and Stewart 2002).
Several pathways exist to repair different types of DNA damage (de Boer and
Hoeijmakers 2000). DSBs are repaired by homologous recombination-dependent repair or
end-joining, and most small base modifications are repaired by base excision repair. Bulky,
helix-distorting adducts caused by UV radiation, some chemicals, and oxidative damage
are repaired by nucleotide excision repair (NER) in mammalian cells (de Laat et al. 1999).
Lower eukaryotes can repair UV-induced DNA damage also by the photolyase enzyme
(Thoma 1999). Considerable overlap exists in the substrate specificity and some proteins
taking part in the different DNA repair processes.
Tumor suppressor p53 and transcriptional changes in cellular stress responses to UV radiation
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Figure 3. Signal pathways in DNA
damage checkpoint controlling G1/S
phase transition. DNA damage (IR or
UV radiation) activates ATM and ATR
kinases,  which phosphorylate
downstream targets Chk1/2 and p53. In
addition, degradation of cyclin D is
promoted by an unknown mechanism.
These events lead to inactivation of
cyclin E/Cdk2 complexes by inhibitory
phosphorylation of Cdk2 or increased
interaction with inhibitory protein
p21Cip1, and respective inhibition of
G1/S transition.
Apoptosis
An organized cell suicide program, apoptosis, is critical for organ development and
tissue homeostasis in multicellular organisms (Baehrecke 2002). In addition, when cells
are surmounted with irreparable amount of damage, the checkpoint functions can lead to
activation of apoptosis to remove potentially hazardous cells from an organism. Contrary
to necrosis, a pathological form of cell death, apoptosis allows a cell to die without
inducing an inflammatory response in the surrounding tissue (Baehrecke 2002, Leist and
Jäättelä 2001). Apoptotic process depends on numerous extra- and intracellular pro- and
antiapoptotic signals which are integrated to activate apoptotic effectors only when
necessary. Two separate, but crosstalking, mechanisms of apoptosis induction have been
identified (Gupta 2001). In the first one, intracellular death messengers lead to disruption
of mitochondrial membrane potential (Wang 2001). The following release of cytochrome c
from mitochondria activates the apoptotic executors, cysteic proteases called caspases
(Earnshaw 1999). Alternatively, signals from membrane-bound death receptors can lead to
mitochondria-independent activation of caspases (Gupta 2001). The morphological
apoptotic changes, including DNA fragmentation, nuclear condensation, loss of cell
volume, and membrane blebbing (Kerr  et al. 1972), usually result from the activity of
caspases, but also caspase-independent pathways of programmed cell death exist (Leist
and Jäättelä 2001). Finally, the remaining apoptotic bodies are engulfed by the surrounding
cells (Baehrecke 2002).
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Cancer
The checkpoint functions are not bullet proof, and over time DNA accumulates changes
(Hoeijmakers 2001). This may lead to genomic instability and contribute to tumorigenesis
when mutations occur and subsequently change behavior of genes controlling the cell
cycle, DNA repair, cellular life span, apoptosis, and intercellular communication and
interactions (Hanahan and Weinberg 2000). Incidence of many types of cancers in human
population increases with age, and it has been proposed that over six consecutive changes
must occur for a cancer to form (Fearon and Vogelstein 1990). To be able to proliferate
despite the restraints posed by its environment, a tumor cell must obtain self-sufficiency in
growth signals and insensitivity to growth-inhibitory signals. It must also be able to evade
from apoptosis and obtain limitless replicative potential. At a later stage in tumor
development, malignant growth requires sustained angiogenesis and ability to invade the
surrounding tissue and metastasize (Hanahan and Weingberg 2000).
Alterations in two types of genes contribute most to formation of cancer. Proto-
oncogenes promote tumorigenesis by a dominant gain of growth-promoting function.
Tumor suppressor genes normally suppress carcinogenic progression; a function which is
recessively lost to enable tumorigenesis. These often have opposing functions in the same,
crucial cellular pathways. For example, the Rb pathway, critical for controlling normal cell
proliferation and targeted in most - if not all - human cancers, harbors several oncogenes
and tumor suppressor genes (Figure 4) (Ho and Dowdy 2002). The other major pathway
targeted in human cancers is the tumor suppressor p53 pathway which functions in the
damage checkpoints. Important proto-oncogenes include growth-promoting c-Myc,
signaling molecule Ras, and anti-apoptotic Bcl-2 (B-cell lymphoma 2) (Pelengaris et al.
2002, Coultas and Strasser 2003, Downward 2003). Several DNA repair- and apoptosis-
promoting genes act as tumor suppressor genes, such as the mismatch repair genes MSH2
(mutS homolog 2) and MLH1 (MutL homolog 1), Apaf-1 (apoptotic protease activating
factor 1), and some of the caspases (Macleod 2000). Cell origin and tissue environment
affect tumorigenesis, and many oncogenes and tumor suppressor genes are crucial mostly
for a certain type of cancer originating from differentiated tissue, e.g. Brca1 for breast
tumors, and APC (Adenomatous polyposis of the colon) for colon cancer (Fearon and
Vogelstein 1990, Macleod 2000).
Figure 4. Proto-oncogenes and tumor suppressor genes often have opposite functions in the cellular
pathways controlling cell proliferation and apoptosis. As an example, the Rb pathway controlling cell cycle
entry is shown. The pathway contains several proto-oncogenes (ovals) and tumor suppressor genes (boxes),
whose disturbed functions are associated with tumorigenesis.
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ULTRAVIOLET RADIATION
UV light is electromagnetic radiation emitted from the sun (or an artificial source)
invisible to human eye. UV radiation is divided to three areas according to its wavelength:
UVA 320-380 nm, UVB 290-320 nm, and UVC 190-290 nm (Figure 5). Energy content of
the radiation is inversely correlated to its wavelength, rendering UVC the most potentially
harmful part of UV light (Tyrrell 1994). The ozone layer absorbs solar UVC and most of
UVB. At present, 1-10% of UV radiation on Earth surface is UVB and over 90% UVA, but
the proportion of shorter wavelengths is increasing due to stratospheric ozone depletion
(Lloyd 1993). UV radiation has many effects on skin, including inflammation,
immunosuppression, alterations in the extracellular matrix (ECM), and accelerated aging
(Norval 2001, Wlaschek et al. 2001). In addition, UV radiation harms the eyes especially
by promoting age-related ocular diseases (Roberts 2001). The most hazardous effect of
increasing UV light for humans is, however, increased risk of skin cancers (de Gruijl 1999,
Armstrong and Kricker 2001).
Cellular damage caused by UV radiation
Organic material can be harmed by absorbed UV radiation. Cells contain photosensitive
molecules, chromophores, which can receive photons from the radiation and subsequently
lift electrons to a higher energy state. This excitation can occur only when the energy of
the photon is close to the difference between the energy states of the electron. A
chromophore can pass its excited energy to another molecule and cause a chain reaction
(Tyrrell 1994). The occurrence and nature of these events depend on the chemical structure
of the chromophore, wavelength of radiation, and specific reaction conditions. Due to the
complexity and amount of different biomolecules, UV radiation can cause various events
within a cell (Figure 5). These photobiological events can occur extremely fast, but their
consequences may be detectable years afterwards, e.g. in the form of cancer (Tyrrell 1994,
de Gruijl 1999).
The main cellular chromophores for UV radiation are DNA and oxygen-dependent
chromophores. Because of the ring structures of its bases, DNA absorbs short wavelength
UV very efficiently (de Gruijl et al. 2001). It is the main chromophore for UVC and
absorbs a significant amount of energy also in UVB wavelenghts (Ravanat et al. 2001).
UV radiation can cause several types of damage to DNA molecules. The most apparent are
cyclobutane-type pyrimidine dimers (CPDs) and (6-4)-photoproducts (6-4PPs), which
crosslink adjacent DNA bases (Ravanat et al. 2001). These UV-induced DNA bulges halt
RNA polymerase elongation along the DNA, thus inhibiting gene expression (Tornaletti
and Hanawalt 1999). Oxidative events become increasingly important in the longer
wavelengths and are the main damage caused by UVA (Kielbassa et al. 1997) (Figure 5).
Oxygen-requiring events provoked by UV radiation are divided into two types. The first
involves an excited photosensitive molecule joining to oxygen to form a reactive radical.
In the second, an excited molecule transfers energy or an electron to oxygen, forming
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either a singlet oxygen or a superoxide anion radical. Via these reactive oxygen species
(ROS), UV radiation induces oxidative stress in cells causing e.g. lipid peroxidation and
additional types of DNA damage. Longer wavelength UV radiation can induce relatively
small amounts of DNA breaks and DNA-protein crosslinks. UV radiation can also harm
lipids and proteins, but the reproducibility of these cellular molecules makes them
biologically less significant chromophores. Large amounts of UV radiation can, however,
induce degeneration of the inner and outer cellular membranes, inhibition of
macromolecular synthesis, and a chaotic state in cellular metabolism (Tyrrell 1994).
Figure 5. UV radiation and the types of cellular damage it causes. UV light is divided to three wavelength
areas (UVA, UVB, UVC). Solar UVC is mostly restrained in the stratospheric ozone layer. The damage
which UV radiation inflicts on cellular chromophores depends on its wavelength, which is inversely
correlated to its energy content.
Cellular adaptation to UV radiation-induced damage
Both oxidative and DNA damage caused by UV radiation provoke adaptive cellular
responses by inducing repair events, signaling cascades, and changes in transcription (de
Gruijl et al. 2001, Bender et al. 1997). Repair of UV-induced DNA lesions is launched
immediately after a UV insult. At the same time, both a cellular response, either a
replication arrest or apoptosis, and paracrine events are induced (Kulms and Schwarz
2000, Decraene et al. 2001). The latter involves changes in the ECM and signaling to
initiate inflammation and the following photoprotective responses in skin as an organ
(Clydesdale et al. 2001, Sturm 1998). These events are mediated by several cellular
signaling cascades targeting pre-existing pools of transcription factors, which then change
the gene expression pattern of the cell to achieve an adaptive transcriptional response
(Bender et al. 1997).
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Cellular response pathways induced by UV radiation
The DNA damage induced by UV radiation triggers several signaling cascades.
Activated ATR leads to phosphorylation of Chk1 kinase, immediate cell cycle arrest
through degradation of Cdc25, and activation of tumor suppressor p53-dependent
prolonged cell cycle arrest. If the UV damage is successfully repaired, the cells are
eventually allowed to re-enter the cell cycle by yet unidentified mechanisms (Bartek and
Lukas 2001a). DNA damage is thought to be the main trigger of UV-induced cell cycle
arrest and apoptosis, but UV radiation has also several other means to provoke a cellular
response (Kulms and Schwarz 2000). It induces clustering and internalization of several
cell surface growth factor and cytokine receptors independently of their ligands (Rosette
and Karin 1996). This results in activation of the respective downstream signaling
cascades, the major signal transducers being mitogen-activated protein (MAP) kinases
JNK (jun N-terminal kinase) and p38 (Bode and Dong 2003). Intracellular increase in ROS
activates MAP kinases through activation of Raf and MEKK1 (Rittie and Fisher 2002).
UV radiation induces also GTP-binding protein family members Ras, Rac, and Cdc42,
which act upstream of MAP kinases Erk, JNK, and p38 (Takai et al. 2001). MAP kinases
are induced dependently on the dose, time, and wavelength of UV radiation, subsequently
acting in the regulation of cell growth control, survival, chromatin remodeling, and
apoptosis (Bode and Dong 2003).
Several transcription factors take part in the UV response, of which AP-1 (activating
protein 1), NFκB (nuclear factor κB), and p53 are the most recognized and well
characterized ones (Bender et al. 1997). AP-1 is a transcription factor family inducing
different sets of target genes and responses depending on the activating stimuli. After UV
radiation, AP-1 seems to mostly work in an antiapoptotic fashion (Schreiber et al. 1995,
Wisdom et al. 1999) and regulate several ECM proteins (e.g. matrix metalloproteinases,
type I procollagen) (Rittie and Fisher 2002). NFκB is activated both by UV radiation-
induced DNA damage and plasma membrane-originated events (Legrand-Poels et al.
1998). DNA damage provokes NFκB-dependent production of immunoregulatory
cytokines involved in contact hypersensitivity, inflammation, and immune suppression.
NFκB is thought to act mainly in an antiapoptotic manner, but it has both anti- and
proapoptotic properties (Bours et al. 2000). The response resulting from NFκB activation
is determined in collaboration with other stress-responsive pathways, especially that of p53
(Ryan et al. 2000).
Nucleotide excision repair
Helix-distorting DNA bulges, such as those induced by UV radiation, are repaired by
NER. It involves 20-30 proteins each with specific functions (de Boer and Hoeijmakers
2000). Most proteins in NER recognition and incision steps have been identified and
named according to seven complementation groups of Xeroderma pigmentosum (XP), a
photosensitivity disorder resulting from deficient NER (XPA to XPG) (Hanawalt 1998).
When the NER repair complex has access to a UV lesion, DNA is opened around the
injury. The damaged strand is incised at approximately 15 nucleotides from both sides of
the bulge, and the lesion-containing piece is removed. Finally, new DNA is synthetisized
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and ligated to fill the place of the removed sequence (de Laat et al. 1999, de Boer and
Hoeijmakers 2000). UV damage causes local inhibition of transcription around the
damaged areas in the nucleus through deprivation of TFIIH, which is needed for both NER
and transcription initiation (Moné et al. 2001).
There are two mechanistically different subtypes of NER, transcription-coupled repair
(TCR) and global genomic repair (GGR) (Hanawalt 2002). TCR occurs relatively rapidly
and only repairs the template strand of transcriptionally active DNA. GGR, on the other
hand, occurs slower repairing also the non-template strand and the non-transcribed areas.
Cell survival depends more on TCR than GGR (Ljungman and Zhang 1996), but,
eventually, genomic integrity is influenced more by GGR (Hanawalt 2001). As GGR is
launched by XPC-hHR23B protein complex recognizing UV-type of DNA damage
(Sugasawa et al. 1998), TCR is probably triggered by RNAPII complexes halting at UV-
induced DNA bulges (Tornaletti and Hanawalt 1999). In TCR, when repair enzymes are
recruited, they must remove the polymerase to access the lesion. This occurs either by
ubiquitination and the following degradation of RNAPII (Ratner et al. 1998), or by some
other, still unresolved mechanism (Hanawalt 1998). In addition, TCR requires CS-A and
CS-B proteins not needed for GGR, the deficiency of which results in UV radiation
hypersensitivity disorder Cockayne syndrome (Venema et al. 1990).
Role of UV radiation in skin carcinogenesis
The damage induced by solar UV radiation contributes to all skin cancer types,
including basal cell carcinoma, squamous cell carcinoma, and cutaneous melanoma. All
these cancer types show correlation to sun exposure, either the total sun exposure in long
term or episodes of sunburn (de Gruijl et al. 2001). Importance of NER in suppressing UV-
induced tumorigenesis is highlighted in the extremely tumor-prone phenotype of most XP
complementation groups (Kraemer et al. 1994). Deficiency in DNA repair of a UV-lesion
may result in a mutation within the next two rounds of cell division, since the damaged
bases are often misinterpreted during DNA replication. Conventional DNA polymerases
cannot bypass a UV lesion, but a specific DNA polymerase (η) can, although only by
inserting an adenine opposite to the lesion (de Gruijl et al. 2001). Even though this activity
is controlled by a proofreading exonuclease (Bebenek et al. 2001), mutations frequently
occur, leading almost exclusively to C to T transitions (de Gruijl et al. 2001). UV acts as
an initiator of carcinogenesis through the DNA damage it causes, but also promotes
tumorigenesis by inducing local and systemic immunosuppression (Clydesdale et al.
2001).
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TUMOR SUPPRESSOR p53
p53 is a central, damage-responsive transcription factor which governs the adaptive and
protective cellular stress responses (Levine 1997). It is activated following several types of
exo- and endogenous cellular damage, such as DNA damage, hypoxia, nucleotide
imbalance, oxidative damage, and spindle damage (Figure 6). It also reacts to alterations in
cell proliferation induced by activation of oncogenes or viral transformation. Upon
activation, p53 determines the fate of the cell based on the severity of the damage. It can
halt progression of the cell cycle and direct damage repair. On the other hand, if a
particular cell has suffered extensive and unrepairable damage, p53 induces apoptosis
(Prives and Hall 1999, Vousden and Lu 2002). p53 elicits its normal functions mainly by
acting as a transcription factor, and it regulates genes contributing to the cell cycle, DNA
repair, and apoptosis. Even though p53 was found over 20 years ago and has been
vigorously studied ever since (May and May 1999, Prives and Hall 1999), it is not yet clear
what determines whether a transient protective response or a terminal apoptotic response is
induced by p53 following a certain insult.
As p53 protein is potentially very harmful to cells, it must be kept well controlled under
normal cell growth conditions. Yet, it has to react to a variety of stress signals rather
quickly and to function in a complex manner upon activation. Thus, it is not unexpected
that p53 is subject to several regulating mechanisms and can interact with dozens of other
proteins (Prives and Hall 1999). Distinct activation pathways exist for p53, and they show
specificity for e.g. stress stimulus, cell type, and growth phase. Some general mechanisms
are common for these pathways: p53 protein level is constantly balanced between
synthesis and degradation, and this most often includes regulation by the inhibitory factor
Murine double minute 2 (Mdm2). The intrinsic activity of p53 protein can also be
modulated, as well as its localization and interactions with other proteins. Altered
posttranslational modifications of p53 are often included in these different modes of
regulation (Meek 1999, Appella and Anderson 2001). The net effect of all these events
contribute to the outcome of a cellular response driven by p53 activation.
Through its actions to prevent cellular functions from becoming abnormal, or to even
destroy aberrant cells, p53 acts as an essential tumor suppressor. Over 50% of human
tumors harbor TP53 mutation, which renders the p53 protein functionally impaired. This
makes TP53 the most commonly mutated gene in human cancers. It is also speculated that
the rest of human tumors have dysfunctional p53, through, for example, disturbed
regulation or protein-protein interactions, and that functional impairment of p53 is required
for malignant tumor development (Vousden and Lu 2002). Loss of p53 function does not
seem to be connected with the first steps of tumorigenesis, but with the transformation of a
benign tumor to a malignant cancer.
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Figure 6. Tumor suppressor p53 is
activated by several forms of
cellular stress, which induce either
p53-mediated cell cycle arrest or
apoptosis.
Structure of p53
The TP53 gene is located in the short arm of chromosome 17 (17p13) and belongs to a
family with three identified members in mammalian cells to date. The gene spans about 20
kb and contains 11 exons, of which the first exon is non-coding and localized 8-10 kb
away from exons 2-11 (Benchimol et al. 1985, Isobe et al. 1986, McBride et al. 1986,
Miller et al. 1986). TP53 codes for a protein which is relatively well conserved in
evolution (Soussi et al. 1987) especially in five regions (amino acids 13-23, 117-142, 171-
181, 234-250, 270-286; designated as I-V, Figure 7) (Soussi et al. 1990). Human p53 is
393 amino acids long and has a molecular mass of 53 kDa. As most transcription factors,
p53 has several distinct, but inter-dependent, functional domains with specific properties
(Prives and Hall 1999) (Figure 7). Transactivation domain (TAD; amino acids 1-42) is
located in the amino-terminal (N-terminal) part of the protein next to a proline-rich area
(63-97). Sequence-specific DNA binding is mediated through the central core of p53 (102-
292). Carboxy-terminal (C-terminal) part of p53 composes of a flexible linker region (300-
318), oligomerization domain (323-356), and a basic, regulatory C-terminal domain (CTD;
363-393) (May and May 1999, Prives and Hall 1999).
The TAD is acidic allowing p53 to recruit basal transcription machinery when bound to
DNA. The TAD can directly interact with TBP and TBP-associated factors (TAFs) of
TFIID (Lu and Levine 1995, Thut et al. 1995).  The N terminus of p53 can also interact
with replication protein A (RP-A) and p62 subunit of TFIIH (Dutta et al. 1993, He et al.
1993, Li and Botchan 1993, Xiao et al. 1994). Amino acids 22-23 in the conserved region I
have a key role in p53 transcriptional activity (Lin et al. 1994). Many p53 inhibitory
proteins, like Mdm2 and several viral proteins, bind to this region blocking the
transcriptional activity of p53 (Prives and Hall 1999). The Pro-rich area of p53 has a series
of repeated proline residues typical for interactions with SH3-binding domain-containing
signal molecules (Gorina and Pavletich 1996). The exact function of this regulatory
domain remains unclear, but it is needed for p53 to induce apoptosis in some systems
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(Sakamuro et al. 1997) and to mediate tumor cell growth suppression (Walker and Levine
1996). Deletion of the Pro-rich domain does not influence transcriptional activity of p53
directly, but alters p53-mediated transrepression, as well as the stability and DNA binding
of the protein (Müller-Tiemann et al. 1998, Venot et al. 1998, Berger et al. 2001, Dumaz
et al. 2001).
The DNA binding domain of p53 interacts sequence-specifically with double-stranded
DNA (Kern et al. 1991, Bargonetti et al. 1991). Its central core is composed of a large β-
sandwich and three loop-based elements (Cho et al. 1994) (Figure 7). Loop 1 (L1) contacts
DNA within the major groove and loop 2 (L2) within the minor groove. Loop 3 (L3) packs
against L1 and stabilizes it. L2 and L3 are connected by a zinc-atom (Zn2+) tetrahedrally
coordinated on amino acids Cys176, His179, Cys238 and Cys242 in their reduced state,
which stabilizes the loops. The loops overlap with four conserved regions which contain
the major mutational hot spots of p53 (Pavletich et al. 1993, Bargonetti et al. 1993, Wang
et al. 1993), underlining the importance of DNA binding for tumor suppressive function of
p53. The most frequent cancer-associated p53 mutations occur on Arg248 and Arg273,
residues directly contacting DNA. The second most frequent type of cancer-related p53
mutations target residues which are structurally stabilizing. In solution, p53 is
predominantly as tetramers, which are the most effective oligomer forms in terms of DNA
binding (Kraiss et al. 1988, Clore et al. 1995). Tetramerization occurs through the
oligomerization domain of p53, which has a β-sheet-turn-α-helix-motif governing the
formation of a dimer of dimers (Waterman et al. 1995).
The C terminus of p53 recognizes DNA and possesses autonomous DNA binding and
strand reassociation ability, but no sequence-specificity in itself (Prives and Hall 1999).
The CTD is predominantly composed of basic residues, and it can be heavily modified
posttranscriptionally. The CTD regulates sequence-specific DNA binding of p53, but the
mechanism is not entirely resolved (Hupp 1999, Ahn and Proves 2001, Yakovleva et al.
2002; see later). The CTD can also bind RNA and is postulated to recognize DNA damage
as it binds DNA ends and single-stranded DNA (Bakalkin et al. 1995), mismatches (Lee et
al. 1995), Holliday junctions (Lee et al. 1997), and DNA irradiated with IR (Reed et al.
1995).
Figure 7. Structure of p53 protein. See text for details.
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Regulation of p53 stability by degradation through the proteasome
During normal metabolism in eukaryotic cells, the 26S proteasome degrades most
proteins outside the lysosomal pathway  (Kierszenbaum 2000). It recognizes its targets by
ubiquitin, a small, 8.5-kDa protein which can be covalently linked to lysine residues of
proteins (Weissman 2001). Targeting proteins to degradation via the proteasome pathway
is the most important function known for ubiquitin ligation so far (Hochstrasser 1996).
Target proteins can be either monoubiquitinated with single ubiquitin molecules or
polyubiquitinated with ubiquitin chains (Weissman 2001). However, only
polyubiquitination promotes degradation (Thrower et al. 2000). At least three types of
enzymes are needed to mediate ubiquitination of a protein. First, an E1 ubiquitin-activating
enzyme sequesters a ubiquitin molecule, transfers it through an E2 ubiquitin-conjugating
enzyme to an E3 ubiquitin ligase, which, finally, conjugates the ubiquitin on the target
protein. Usually, E3 ligases recognize substrates and determine the specificity of the
ubiquitination process (Weissman 2001). An additional enzyme, E4, is involved in the
assembly of the branched ubiquitin polymers in the polyubiquitination process (Koegl et
al. 1999).
p53 is expressed constantly, but its levels are kept low by continuous protein
degradation (Prives and Hall 1999). Under normal cellular growth conditions, p53 has a
half-life of less than 20-30 min. Upon stress, p53 is accumulated to cells. This occurs by
blocking its degradation, which leads to increased protein half-life, rather than by
upregulating gene expression or mRNA stability. p53 is degraded through the 26S
proteasome; a process which is driven by the ubiquitination of p53 to several C-terminal
lysine residues (Rodriguez et al. 2000). The major E3 ubiquitin ligase for p53 is Mdm2,
the most important regulator of p53 (Momand et al. 2000, Alarcon-Vargas and Ronai
2002). Mdm2 inhibits the transcriptional activity of p53 by binding to the p53 TAD
(Juven-Gershon and Oren 1999, Momand et al. 2000) and ubiquitinating p53 and itself,
leading to degradation of the proteins (Honda et al. 1997, Haupt et al. 1997,  Kubbutat et
al. 1997). However, Mdm2 can only monoubiquitinate p53 (Lai et al. 2001), and it relies
on its ability to bind p300 to mediate p53 degradation (Grossman et al. 1998, Zhu et al.
2001). This was recently shown to be due to an intrinsic ubiquitin ligase activity of p300,
by which it performs p53 polyubiquitination (Grossman et al. 2003).
Even though it is believed that Mdm2 shuttles p53 from nucleus to cytoplasm (Roth et
al. 1998), nuclear export is unessential for p53 degradation (Yu et al. 2000, Lohrum et al.
2001, Xirodimas et al. 2001), and p53 can be degraded by both cytoplasmic and nuclear
proteasomes (Shirangi et al. 2002). After stress, p53 accumulation occurs through
weakening of p53-Mdm2 interaction, which can be achieved by two mechanisms:
inhibition of Mdm2 by interacting proteins, or changes in posttranslational modifications
of p53 and/or Mdm2 (Figure 8). The best characterized Mdm2-interacting protein capable
of inhibiting p53 degradation is the alternative reading frame protein (ARF), which is
induced by e.g. oncogene activation (Sherr and Weber 2000) (Figure 8; see below). HIF-
1α (hypoxia inducible factor 1α) also interacts with Mdm2 and thereby inhibits p53
degradation (Chen et al. 2003). Mdm2 is induced by p53, creating an autoregulatory loop
to downregulate p53 at the end of a stress response (Juven-Gershon and Oren 1999,
Momand et al. 2000). Recently, another E3 ligase for p53 was identified: Pirh2 can
ubiquitinate p53 in vitro and promote p53 degradation in vivo independently of Mdm2
(Leng et al. 2003). Interestingly, Pirh2 is a p53 target gene, possibly forming a feedback
regulatory loop (Leng et al. 2003).
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Figure 8. Regulation of p53 protein. See text for details.
Mdm2
Mdm2 (in human cells also referred to as Hdm2) is an oncogene due to its inhibitory
effects on p53 (Deb 2002). It has also p53-independent properties relevant to tumor
suppression, presumably through its interactions with the cell cycle regulators Rb and
E2F1 (Momand et al. 2000, Daujat et al. 2001). HDM2 gene is located on chromosome
12q13-14, a region often amplified in human cancers. As an alternative to p53 mutation,
overexpression of Mdm2 protein is a tumor-associated mechanism to inactivate p53, and
amplification of HDM2 occurs in 7% of human cancers (Momand et al. 2000). Nuclear
exclusion represents an additional, Mdm2-related mechanism to abrogate p53 function
(Liang and Clarke 2001, Stommel et al. 1999). Knock-out (KO) of Mdm2 in mice is
embryonic lethal, a phenotype which can be rescued in a p53-null background, underlining
the importance of Mdm2 in inhibiting p53 activity (Montes de Oca Luna et al. 1995, Jones
et al. 1995).
The major Mdm2 transcript in human cells codes for a 90-kDa protein with 491 amino
acids and a RING finger motif on its C terminus, responsible for the E3 ubiquitin ligase
activity (Momand et al. 2000). Several regulatory phosphorylation sites on Mdm2 have
been identified both in its N terminus, which binds p53, and in its central acidic domain
mediating p53 ubiquitination (Hay and Meek 2000). Mdm2 is phosphorylated by Akt
kinase, which promotes nuclear translocation of Mdm2 and its ability to ubiquitinate
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p53 (Mayo and Donner 2001, Zhou et al. 2001, Ashcroft et al. 2002, Lin et al. 2002).
Other Mdm2 modifications which may influence Mdm2 ability to promote p53
degradation are phosphorylation on Ser395 by ATM (Maya et al. 2001), on Ser267 by
casein kinase 2 (CK2) (Hjerrild et al. 2001), on Thr218 by cyclin A-containing CDK
complexes (identified from Thr216 in murine Mdm2 by Zhang and Prives 2001), and on
Tyr394 by c-Abl (Goldberg et al. 2002). After IR, dephosphorylation of several residues in
the central domain of Mdm2 decreases Mdm2 ability to promote p53 degradation (Blattner
et al. 2002).
A recently cloned Mdm2 homologue, MdmX, is also capable of inhibiting p53-
mediated transactivation (Stad et al. 2000). MdmX does not promote degradation of p53,
but can inhibit Mdm2 doing so, thus stabilizing both p53 and Mdm2 (Jackson and
Berberich 2000, Stad et al. 2001). The significance of MdmX-mediated regulation of p53
in DNA damage responses is unclear. Levels of MdmX do not change after DNA damage,
but it might be regulated by translocation from cytoplasm to nucleus (Shvarts et al. 1996,
Li et al. 2002a). MdmX is overexpressed in some tumors, and its gene MDM4 amplified,
correlating with elevated levels of p53 (Ramos et al. 2001). Loss of the Mdm4 gene in
mice is embryonic lethal and can be rescued with loss of p53. This suggests that Mdm2
and MdmX work in non-overlapping pathways to regulate p53 (Parant et al. 2001).
ARF
ARF  (p14ARF in human, p19ARF in mice) is produced from an alternative reading frame
of the INK4a locus which also codes for the CKI protein p16Ink4a (Quelle et al. 1995), thus
linking the p53 and Rb pathways important for suppression of tumorigenesis. ARF is a
small, basic protein which interacts with the C terminus of Mdm2, abrogating the ability of
Mdm2 to promote p53 degradation (Kamijo et al. 1998, Pomerantz et al. 1998, Stott et al.
1998, Zhang et al. 1998, Honda and Yasuda 1999). ARF is able to translocate Mdm2 to the
nucleoli (Weber et al. 1999), but this is not required for inhibition of Mdm2 activity
(Llanos et al. 2001). ARF is also capable of interacting with MdmX and sequestering it to
the nucleoli, resulting in an increase in the transcriptional activity of p53 (Jackson et al.
2001). ARF responds to abnormal cell proliferation resulting from oncogenic stimulus and
viral transformation, and it can be induced by at least Myc (Zindy et al. 1998), Ras
(Palmero et al. 1998), E2F1 (Bates et al. 1998), and adenoviral E1A (de Stanchina et al.
1998). Induction of ARF causes growth arrest and represses transformation through
induction of p53 (Quelle et al. 1995, Kamijo et al. 1997, Pomerantz et al. 1998). In
addition, ARF-null cells immortalized in cell culture often retain functional p53,
suggesting that suppression of cellular transformation by p53 is mediated by ARF (Kamijo
et al. 1997). Interestingly, ARF, Mdm2, and p53 triple-null mice develop tumors with a
greater frequency than p53/Mdm2 double-null or p53 KO mice, suggesting that ARF has
other tumor-suppressive functions in addition to regulation of p53-Mdm2 pathway (Weber
et al. 2000). These may be due to the ability of ARF to induce antiproliferative genes and
to inhibit ribosomal RNA processing independently of p53 (Kuo et al. 2003, Sugimoto et
al. 2003). ARF is not essential for the DNA damage response of p53 (Kamijo et al. 1997).
p53 negatively regulates ARF expression, thus returning the ability of Mdm2 to
downregulate p53 (Stott et al. 1998).
Review of the literature
31
Other p53-interacting proteins
In addition to Mdm2, p53 is found to interact with over 100 proteins which regulate or
contribute to multiple p53 functions (Prives and Hall 1999, Vousden and Lu 2002). p53 is
regulated by several enzymes modifying it posttranslationally, most of them being kinases
(described in more detail below). As a typical transcription factor, p53 interacts with
several transcription-related proteins. Interaction with HATs, such as p300/CBP, and
histone deacetylases (HDACs) affect both chromatin structure and acetylation status of
p53. Interactions with basal transcription factors TBP, TFIIH, and TAFs, and other
transcription factors like Sp1 and Oct-1, promote formation of an active RNAPII initiation
complex (Levine 1997, Prives and Hall 1999).
Examples of other proteins affecting p53 functions by protein-protein interactions are
WT-1 (Wilms tumor-1), which interacts with p53 stabilizing it and inhibiting p53-mediated
apoptosis (Maheswaran et al. 1995), redox/repair protein Ref-1 (redox factor 1), which is a
potent activator of p53 DNA binding and transactivation (Jayaraman et al. 1997), and
p33ING1 (inhibitor of growth 1) (Garkavtsev et al. 1998). ASPP1 and ASPP2 (apoptosis
stimulating proteins of p53 1 and 2) are proapoptotic, p53-interacting proteins, which
regulate the activity of p53 towards a subset of target genes (Vousden and Lu 2002). The
central region of p53 binds 53BP1 (p53 binding protein 1), which is a DSB-responsive
checkpoint protein able to stimulate p53-dependent transactivation (Abraham 2002). p53
interacts with e.g. NER proteins XPB and XPD (Wang and Prives 1995), DNA replication
factor RP-A (replication protein A), and DNA repair protein Rad51 (Buchhop et al. 1997)
to promote DNA repair. In addition, p53 interacts with other stress-responsive proteins,
such as PML (promyelocytic leukemia protein) and heat shok factors Hsp40, Hsp70, and
Hsp90 (Prives and Hall 1999). The significances of these interactions are not entirely clear,
however.
As p53 can sense abnormal proliferation and its activity can lead to destruction of the
cells, several viruses have evolved a mechanism to inactivate it. p53 was originally
identified as the cellular factor targeted by the large T antigen of Simian virus 40, which
binds to p53 and inhibits its transcriptional activity (Levine 1997). Adenoviral E1B-55kDa
and hepatitis B virus X protein also bind to p53 and inhibit its activity. E6 of human
papilloma virus (HPV) inhibits p53 by serving as an E3 ubiquitin ligase, thereby targeting
p53 to degradation  (Prives and Hall 1999).
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Posttranslational modifications of p53
In addition to ubiquitination, p53 protein can be posttranslationally modified to several
amino acid residues in its N- and C-terminal domains by phosphorylation, acetylation,
sumoylation, and glycosylation (Figure 9) (Meek 1999, Appella and Anderson 2001).
Modifications can occur either basally or inducibly, after for example a genotoxic insult,
and affect p53 activity, its interactions with other proteins, and its localization. Significant
interplay exists between the different p53 modifications (Meek 1999, Appella and
Anderson 2001).
Figure 9. Posttranslational modifications of p53 protein. Amino acid residues available for modification by
phosphorylation (circles), acetylation (hexagons), and sumoylation (octagon), and area of glycosylation are
shown, as well as the most recognized enzymes responsible for certain modifications.
Phosphorylation
Intracellular signaling is largely mediated by kinases and phosphatases. In addition,
transcription factors are often regulated by changes in their phosphorylation patterns
(Holmberg et al. 2002). p53 makes no exception to this rule by containing both in its N-
and C-terminal regions several amino acid residues which can be phosphorylated. Most of
them are modified in response to p53-activating stress signals, but some during normal cell
growth conditions. Phosphorylating kinases for most of these sites have been identified,
and several phosphoacceptor residues can be modified by more than one kinase (Meek
1999, Appella and Anderson 2001, Alarcon-Vargas and Ronai 2002).
N-terminal half of p53 contains seven serine and two threonine residues which are
phosphorylated at least upon IR and UV radiation (Appella and Anderson 2001). Ser15,
Ser20, Ser33, and Ser37 can be phosphorylated by PI-3-like kinases DNA-PK (DNA-
dependent protein kinase), ATM, and ATR (Prives and Hall 1999, Appella and Anderson
2001). In addition, the checkpoint kinases Chk1 and Chk2 phosphorylate Ser20 (Shieh et
al. 2000). Ser9 and Thr18 are phosphorylated by CK1, an event which is facilitated by
prior phosphorylations on Ser 6 and Ser15, respectively (Dumaz et al. 1999, Higashimoto
et al. 2000). Ser33 is phosphorylated by CAK (CDK activating kinase) (Ko et al. 1997),
which is a component of TFIIH, or p38 (Bulavin et al. 1999) in vitro. Based on
experiments on murine p53, Ser33 could also be phosphorylated by JNK (Milne et al.
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1995, Hu et al. 1997). The most N-terminal phosphorylation sites are located in the TAD
and apparently take part in the regulation of transcriptional activity of p53 (Meek 1999,
Appella and Anderson 2001, Alarcon-Vargas and Ronai 2002). Several of these
phosphorylations have been suggested to inhibit the binding of Mdm2 to p53 and thus
increase p53 stabilization. Phosphorylations on Ser15 and Ser37 block Mdm2 binding in
vitro (Pise-Masison et al. 1998, Shieh et al. 1997, Siliciano et al. 1997), but contrasting
reports also exist (Mayo et al. 1997, Dumaz and Meek 1999). Thr18 and Ser20
phosphorylations have reported to weaken Mdm2 interaction (Bottger et al. 1999, Craig et
al. 1999, Unger et al. 1999). Mutation of Ser20 to Ala promotes p53 degradation and
abrogates p53 stabilization by DNA damage (Chehab et al. 1999, Dumaz et al. 2001).
Phosphorylation of p53 by DNA-PK can inhibit MdmX interaction (Jackson and Berberich
1999). The N-terminal phosphorylations may also directly stimulate p53 activity.
Phosphorylation on Ser15 and Ser20 promote p53 binding to p300/CBP (Lambert et al.
1998, Dumaz and Meek 1999, Dornan et al. 2003), and combinatorial phosphorylations on
Ser15 and Ser37 stimulate p53 interaction with TFIID (Pise-Masison et al. 1998).
Ser46 of p53 is phosphorylated by p38 in vitro (Bulavin et al. 1999) and by HIPK2
(homeodomain-interacting protein kinase-2) after UV radiation (D'Orazi et al. 2002).
Phosphorylation on Ser46 promotes UV-induced apoptosis (Bulavin et al. 1999) at least by
increasing p53-induced transcription of apoptosis-promoting p53AIP1 (p53-regulated
apoptosis-inducing protein 1) (Oda et al. 2000a). Thr55 is basally phosphorylated in
unstressed cells (Gatti et al. 2000). Thr81 in the p53 Pro-rich domain is phosphorylated by
JNK, contributing to stabilization and activation of p53 in response to UV radiation
(Buschmann et al. 2001). Thr155 is phosphorylated in unstressed cells, targeting p53 to
degradation (Bech-Otschir et al. 2001).
One phosphorylation site has been identified in the oligomerization domain of p53,
namely Ser315, which can be phosphorylated by S and G2/M phase CDKs to selectively
stimulate p53 binding to a subset of p53 binding sites (Wang and Prives 1995). The N-
terminal domain of p53 is basally phosphorylated on Ser376 and Ser378 in unstimulated
cells. Ser376 is rapidly dephosphorylated after IR (Waterman et al. 1998), which allows
binding of 14-3-3 protein to p53 and increases p53 transcriptional activity. These residues
lie within the epitope of antibody PAb421 (residues 371-380), an area which is
phosphorylated by PKC (protein kinase C ) (Meek 1999). PKA (protein kinase A)
(Waterman et al. 1998) and CAK (Lu et al. 1997) also phosphorylate Pab421 epitope at
least in vitro.
The most C-terminal phosphorylation site, Ser392, activates specific DNA binding and
transcriptional activity of p53, presumably by stabilizing p53 tetramers (Hupp et al. 1992,
Sakaguchi et al. 1997). Ser392 can be modified by CK2 (Meek et al. 1990) and dsRNA
activated protein kinase PKR (Cuddihy et al. 1999). Phosphorylation on Ser392 may
selectively regulate p53-mediated transrepression (Hall et al. 1996), and it occurs upon UV
radiation, but not in response to IR (Appella and Anderson 2001).
The significance of p53 phosphorylations has been questioned by experiments showing
that mutations on key phosphorylation sites on N or C terminus have no effect on p53
stabilization by UV radiation or IR (Blattner et al. 1999, Ashcroft et al. 1999), the
transcriptional activity of p53 (Fiscella et al. 1994, Fuchs et al. 1995, Ashcroft et al. 1999),
or its interaction with Mdm2 (Ashcroft et al. 1999). There are also differences between
modifications on murine and human p53 (Meek 1999). In addition, lack of tumor-
associated mutations on the modification sites of p53 argue that phosphorylations are
dispensable for p53 function (Prives and Hall 1999, Vousden 2002).
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Acetylation
Acetylation of lysine residues by HATs is a common means for regulating activity of
transcription factors (Workman and Kingston 1998, Chen et al. 2001). p53 is acetylated on
several C-terminal residues, which increases sequence-specific DNA binding of p53 and
thus promotes its transcriptional activity (Gu and Roeder 1997). Protein acetylation and
ubiquitination often compete for the same lysine residues (Weissman 2001), and
acetylation of p53 was recently shown to inhibit its ubiquitination (Li et al. 2002b).
Lys320 is acetylated by p/CAF, and Lys373 and Lys382 by p300/CBP, in response to both
IR and UV radiation (Appella and Anderson 2001). The N-terminal phosphorylation and
C-terminal acetylation of p53 are linked. Phosphorylations on Ser15 (Lambert et al. 1998)
and/or Ser33 and Ser37 (Sakaguchi et al. 1998) promote recruitment of HATs and thus
enhance p53 acetylation. Ser20 phosphorylation stabilizes p53 binding to p300 (Dornan et
al. 2003). Mdm2 and MdmX can inhibit p300-mediated acetylation of p53 (Kobet et al.
2000, Sabbatini and McCormick 2002). Indeed, the N-terminal modifications tend to occur
before the C-terminal ones (Chernov et al. 1998), suggesting that stabilization and
activation of p53 by posttranslational modifications are separate, but co-operative, events.
Sumoylation
Modification by covalent attachment of SUMO (small ubiquitin-related modifier; also
called sentrin) is a recently identified means to regulate proteins (Müller et al. 2001).
SUMO is a small, 11-kDa polypeptide closely related to ubiquitin (Verger et al. 2003). It
can be attached to target protein lysine residues within a consensus motif Ψ-Lys-X-Glu
(where Ψ represents a large, hydrophobic amino acid, most commonly Ile or Val, and X
any amino acid) in a process analogous to ubiquitination (Melchior 2000, Verger et al.
2003). Mammalian cells express three different forms of SUMO (SUMO-1, SUMO-2,
SUMO-3), of which only SUMO-2 and SUMO-3 can form polymeric chains (Verger et al.
2003). SUMO conjugation targets include several transcription-related proteins like c-Jun,
HSF2 (heat shock factor 2), IκB (inhibitor of NFκB) and p300 (Melchior 2000, Girdwood
et al. 2003). In addition, PML and several other proteins located to the PML nuclear bodies
are sumoylated (Seeler and Dejean 2001). The exact function of sumoylation has remained
unclear, but the modification may be involved in regulating protein stability by competing
of the same lysine residues as ubiquitin and acetylation (Freiman and Tjian 2003). Most
studies suggest that SUMO alters interaction properties of its targets, often affecting their
subcellular localization (Seeler and Dejean 2001, Verger et al. 2003). p53 can be
sumoylated on Lys386 (Müller et al. 2000) in a process where PIAS1 and PIASxβ (protein
inhibitors of activated STAT) act as specific E3 sumoylation ligases (Kahyo et al. 2001,
Schmidt and Müller 2002). SUMO-1 is suggested to increase the transcriptional activity of
p53 (Gostissa et al. 1999, Rodriguez et al. 1999), although contrasting reports exist (Kwek
et al. 2001, Schmidt and Müller 2002). Controversial is also whether SUMO directs p53
localization to PML nuclear bodies (Fogal et al. 2000, Kwek et al. 2001).
Glycosylation
p53 can be O-glycosylated in the C terminus in a cell type-specific manner (Shaw et al.
1996). Little is known about the occurrence and significance of this modification, but
evidence from myocytes suggests that glycosylation promotes activation of p53, and that
hyperglycemia may induce p53-induced cell death (Fiordaliso et al. 2001).
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Intracellular localization of p53
Cell nucleus is highly organized and is structured by filamentous nuclear matrix.
Transcription by RNAPII takes place at discrete sites in the nucleus (Szentirmay and
Sawadogo 2000). Altering localization of transcription factors both inside the nucleus and
between nucleus and cytoplasm is a powerful means to regulate transcription. p53 is
predominantly located in the nucleus and excluded from the nucleoli. It exists both in free
form and bound to nuclear matrix colocalizing with active transcription sites (Rubbi and
Milner 2000). Interaction of p53 with nuclear matrix is increased after DNA damage (Jiang
et al. 2001). This is mediated at least in part by p53 binding to F-actin, which is induced by
phosphorylation on Ser392 of p53 (Okorokov et al. 2002). In addition, microtubules and
the dynein motor protein participate in the transport of p53 and facilitate its accumulation
in the nucleus after DNA damage (Giannakakou et al. 2000).
Nuclear localization of proteins is often controlled by nuclear localization (NLS) and
export (NES) signals. Basic NLS sequences bind importins α and β to mediate docking to
the nuclear pore complex, thereby initiating nuclear import (Liang and Clarke 2001). p53
C-terminal region has three nuclear localization sequences (NLS1, NLS2, NLS3).
Mutations in NLS1, which is located in the C-terminal linker region (residues 316-325),
render p53 completely cytoplasmic. Mutations in NLS2 (369-375) and NLS3 (379-384) in
the C-terminal basic region result in distribution of p53 in both nucleus and cytoplasm
(Dang and Lee 1989, Shaulsky et al. 1990). Nuclear export of p53-Mdm2 complexes is
thought to be driven mainly by a NES in Mdm2, even though the C terminus of p53
contributes to this process (Lohrum et al. 2001). p53 contains two NESs. The first is
located in the N-terminal Mdm2 binding region (residues 11-27). Phosphorylation on
Ser15 within this region has been suggested to inhibit nuclear export of p53 driven by this
NES (Zhang and Xiong 2001). The second NES is located in the oligomerization domain.
It is masked in p53 tetramers, but is capable of exporting monomeric p53 to cytoplasm
(Stommel et al. 1999, Liang and Clarke 2001). As for most proteins containing a leucine-
rich NES, p53 export is mediated by exportin 1 (also called CRM1) (Liang and Clarke
2001).
Less conventional places for p53 are the nucleolus, where a fraction of p53 colocalizes
with ribosomal RNA transcription sites (Rubbi and Milner 2000), and mitochondria, where
p53 can directly contribute to apoptosis (see below) (Marchenko et al. 2000, Mihara et al.
2003). p53 can also localize to the PML nuclear bodies (Gottifredi and Prives 2001,
Vousden 2002). Although the specific role of PML bodies is not known, they may serve as
centers for transcription factor modification and thus contribute to transcriptional
regulation (Borden 2002). Indeed, the interaction of p53 with PML and the subsequent
localization of p53 to the PML bodies enhance the transcriptional activity of p53 and its
ability to induce apoptosis and cellular senescence (Vousden 2002).
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Regulation of transcriptional activity of p53
Stabilization of p53 is insufficient to induce p53-dependent growth arrest and apoptosis,
for which the transcriptional activity of p53 has to be upregulated (Yakovleva et al. 2002).
On the other hand, stabilization of p53 is not required for its transcriptional activity (Hupp
1999), indicating that stabilization and activation of p53 are at least partly separate events.
This has led to a model in which p53 is thought to exist in a latent state in nonstressed cells
and to become active upon a stress signal (Hupp 1999). Regulation of transcriptional
activity occurs at the levels of p53 ability to bind DNA and to affect formation of an active
RNAPII complex, which depend on posttranslational modifications of p53 and its
interactions with other proteins (Hupp 1999, Vousden 2002).
Transcriptional activation of a target gene by p53 occurs via sequence-specific binding
of the p53 core region to a response element (RE) on the target gene promoter. A
consensus composition of the p53 RE has been defined (El-Deiry et al. 1992), and it
composes of tandem repeats of the 10 bp motif 5’-PuPuPuC(A/T)(A/T)GPyPyPy-3’
separated by 0-13 bp (Pu, purine; Py, pyrimidine). Each half-site binds a dimer of p53,
explaining why p53 tetramers are the most efficient forms in DNA binding (Hupp 1999,
Vousden 2002). The spacing distance between the two decamers is an important
determinant of p53 affinity. Binding is optimal when the decamers are contiguous or
separated in a manner that the two half sites are orientated on the same helical face of
DNA (Wang et al. 1995a). p53 affinity for the REs is further regulated by the local spacial
structures of DNA, such as chromosomal looping and the degree of superhelicity (Hupp
1999). In addition, the redox state of p53 affects its DNA binding ability; reduction leads
to increased binding, as oxidation abolishes it due to a loss of Zn2+ coordination by Cys
residues in the core region (Hainaut and Milner 1993, Rainwater et al. 1995). The Pro-rich
region also affects the transcriptional activity of p53, as its deletion activates sequence-
specific DNA binding of p53 (Müller-Tiemann et al. 1998).
p53 contains two DNA-binding sites (Yakovleva et al. 2002). The CTD of p53 binds
DNA without sequence-specificity, but is capable of regulating the sequence-specific DNA
binding of the p53 core region (Ahn and Prives 2001). Phosphorylation or deletion of the C
terminus, as well as binding of antibodies or small peptides to it, stimulate DNA binding of
p53 in vitro (Hupp et al. 1992, 1995), indicating that the C terminus allosterically regulates
transition between latent and active forms of p53. This model is, however, challenged by
studies showing that p53 conformation is identical with or without the CTD (Ayed et al.
2001). Recent studies also indicate that p53 is bound on DNA in vivo even in unstressed
cells (Kaeser and Iggo 2002), and that modifications of the CTD are not required for DNA
binding and promoter activation (Espinosa and Emerson 2001, Göhler et al. 2002). In
addition, neither mutation of Ser392 nor all of the C-terminal phosphorylation sites have a
significant effect on p53 transcriptional activity (Fiscella et al. 1994, Fuchs et al. 1995,
Ashcroft et al. 1999). The allosterical CTD regulation model may be due to usage of short
oligomers in binding assays (Ahn and Prives 2001), as full-length p53 does not bind to
REs in short DNA fragments unless the CTD is deleted or modulated by phosphorylation,
acetylation, or binding by PAb421 antibody (Yakovleva et al. 2002).
It is clear, however, that the CTD does regulate sequence-specific DNA binding of p53
in vivo (Ahn and Prives 2001). The CTD could compete for binding to DNA with the core
domain (Anderson et al. 1997). This is supported by experiments showing that long,
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nonspecific DNA molecules inhibit sequence-specific DNA binding of full-length, but not
of the CTD-deleted, p53 (Anderson et al. 1997). Alternatively, the CTD may govern p53
binding to DNA, after which p53 slides along DNA until it finds a RE to bind sequence-
specifically to. p53 has been shown to constantly associate with and disassociate from
DNA, and it is able to slide along it (Jiao et al. 2001). In yet another model, CTD is
suggested to regulate p53 binding to only a subset of REs depending on their three-
dimensional conformation. C-terminally unmodified p53 prefers binding to palidromic
REs, which form cruciform structures (REs in head-to-head orientation; Yakovleva et al.
2002). This may be caused by the CTD, which can also bind four-way Holliday junctions
(Lee et al. 1997). Initiation of transcription could be limited to cruciform targets in this
unstressed situation. After stress, modifications of the CTD could be required for p53 to
bind the target sites that are in head-to-tail orientation and do not form cruciform structures
(Yakovleva et al. 2002).
Several hundred genes are known to be regulated, most of them induced, by p53 (El-
Deiry 1998, Vousden and Lu 2002, Zhao et al. 2000). Over 4000 putative p53 target
sequences have been identified in the human genome (Wang et al. 2001b). In addition, not
all p53 REs are similar to the consensus sequence, and p53 binding to target promoters can
be directed by other factors (Vousden and Lu 2002). This leaves the true number of p53
target genes to be clarified. p53 can also specifically repress several promoters, but the
mechanism is poorly understood. p53-mediated transrepression occurs without sequence-
specific DNA binding, and it most likely depends on interactions of p53 with other
proteins, such as TBP (Seto et al. 1992, Ragimov et al. 1993, Truant et al. 1993) and
HDACs via corepressor Sin3 (Murphy et al. 1999).
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Multiple functions of p53
p53 is a very efficient inhibitor of cell growth. Non-stressed cells overexpressing p53
undergo G1 arrest (Diller et al. 1990, Lin et al. 1992) or apoptosis (Yonish-Rouach et al.
1991, Shaw et al. 1992). These can be separate events, but many aspects of the responses
are in common (Vousden and Lu 2002). It is not clear how the decision is made whether
p53 induces cell cycle arrest or apoptosis. p53 has a direct role in determining which
response pathways are activated, but p53-interacting factors are bound to influence the
outcome (Vousden 2000). The decision is affected by survival factors and cross-talk with
other pathways controlling cell proliferation and survival, such as the Rb and NFκB
pathways (Hickman 2002, Vousden and Lu 2002). In addition, the intracellular levels of
p53 affect the outcome, as low levels preferably activate cell cycle arrest and high p53
doses rather induce apoptosis (Chen et al. 1996). Low levels of p53 may in fact protect
cells from apoptosis (Lassus et al. 1996) at least partly due to p53-mediated cell cycle
arrest (Vousden and Lu 2002). p53 mainly excerts its functions by acting as a transcription
factor, but it has other activities as well, such as 3’-5’ exonuclease activity, and ability to
bind DNA lesions and single stranded DNA (Bakalkin et al. 1995, Lee et al. 1995, Janus et
al. 1999).
p53 is not essential for normal development of mice in utero (Donehower 1996). During
embryogenesis, transcriptional activity of p53 is present mainly in the developing nervous
system (Komarova et al. 1997). After DNA damage by IR, p53 can induce apoptotic and
antiproliferative responses in vivo cell type-specifically (Clarke et al. 1994, Midgley et al.
1995). p53 activity is induced by IR mainly in rapidly proliferating tissues, e.g. epithelia of
the small intestine, and in spleen and thymus of the tissues with low proliferation rate
(Gottlieb et al. 1997, Komarova et al. 1997). Interestingly, haplo-insufficiency for p53
function has been detected in mouse models (Gottlieb et al. 1997).
Cell cycle arrest
p53 can arrest the cell cycle in G1 and G2 phases. The most important transcriptional
target for p53-induced G1 arrest is the CKI protein p21Cip1, which is a potent inhibitor of
several CDK complexes (El-Deiry 1993, May and May 1999). In S phase cells, p21Cip1
may act also by binding to PCNA (proliferating cell nuclear antigen) and blocking the
elongation step of DNA replication (Waga et al. 1994). p21Cip1 may also take part in G2
arrest, as it can inhibit cyclin A- and cyclin B-containing CDK complexes (Li et al. 1994),
but it is not essential for the immediate G2 checkpoint response (Levedakou et al. 1995).
p53-induced G2 arrest is enforced by 14-3-3σ which sequesters and inhibits the mitotic
Cdc25C phosphatase (Hermeking et al. 1997). Antiproliferative p53 effects may also be
mediated by induction of BTG2 (Rouault et al. 1996) and repression of Cdk2 (Zhao et al.
2000). p53 also takes part in the spindle checkpoint by preventing mitosis when sister
chromatids have failed to segregate properly (Meek 2000).
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DNA repair
p53 participates in several processes of DNA repair and DNA recombination by
regulating transcription, but also by interacting with components of repair and
recombination machineries. In addition, p53 promotes DNA repair by binding DNA
lesions and functioning as a 3’-5’ exonuclease (Janus et al. 1999). The first p53 target
identified, Gadd45 (growth arrest- and DNA damage-inducible 45), may promote DNA
repair by its association with PCNA (Janus et al. 1999). p53 also induces transcription of a
ribonucleotide reductase gene p53R2, thereby supplying building blocks for DNA repair
after a genotoxic insult (Tanaka et al. 2000, Nakano et al. 2000).
p53 participates in nucleotide excision repair, even though it is not essential for it in
vitro  (Hanawalt 2002). Abrogation of p53 function by mutation (Ford and Hanawalt 1995)
or targeting by viral proteins (Ford et al. 1998) renders cells defective in GGR. Other
studies have argued that p53 contributes also to TCR (Wang et al. 1995b, Mirzayans et al.
1996, Therrien et al. 1999). p53 is essential for efficient GGR of UV-induced CPDs in
human fibroblasts, and it regulates efficiency of GGR repairing both CPDs and 6-4PPs
after UV radiation (Hanawalt 2002). NER-deficient cells accumulate p53 by lower doses
of UV than normal cells, and they have a prolonged p53 response which correlates to
amount of unrepaired CPDs (Dumaz et al. 1997).
The mechanisms how p53 takes part in NER are still unclear (Hanawalt 2002).
Transactivation of p21Cip1 is not required for p53 to promote GGR, arguing that the
induction of cell cycle arrest is dispensable for the effect (Adimoolam et al. 2001, Smith et
al. 2000). The main transcriptional target of p53 for NER is the repair factor p48, but
Gadd45 may be important as well (Hanawalt 2002). p53 also upregulates the NER factor
XPC upon UV radiation (Adimoolam and Ford 2002) and interacts with several TFIIH-
associated NER factors (Wang et al. 1995b). Recently, p53 was suggested to contribute to
UV-induced GGR by recruiting HAT complexes to the sites of DNA damage, thus
promoting chromatin relaxation needed for repair factors to access the DNA lesions (Rubbi
and Milner 2003).
p53 can bind both double- and single-stranded DNA non-sequence-specifically. It also
binds to DSB ends, Holliday junctions, and DNA mismatches (Janus Cet al. 1999).
Binding of p53 to damaged DNA is mediated by the CTD. This has led to a model in
which p53 could sense DNA damage via its C terminus, leading to activation of the
sequence-specific DNA binding and transactivation (Jayaraman and Prives 1995). 3’-5’
exonuclease activity of the p53 core domain is regulated in a manner opposite to the DNA-
binding activity. This biochemical function is suggested to take part in the DNA repair
processes when p53 is in a non-induced state (Janus et al. 1999). p53 associates with RP-A
needed for DNA replication, homologous recombination, and NER (de Laat et al. 1999).
Disruption of p53-RP-A complexes upon UV radiation occur when DNA repair starts
(Abramova et al. 1997). It has been suggested that in its latent state p53 promotes repair of
replication errors by its exonuclease activities while bound to RP-A. Upon UV radiation,
p53 is activated to perform its transcriptional function, as RP-A is released to take part in
NER (Janus et al. 1999).
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Apoptosis
Ability of p53 to induce apoptosis when the damage inflicted on the cell is irreparable
may be the most important of its tumor suppressive functions (Gottlieb and Oren 1998,
Vousden 2000). p53 can induce several genes which contribute to both death receptor
(Fas/APO1, KILLER/DR5, PERP) and mitochondrial (e.g. Apaf-1, Bax, NOXA, p53AIP1,
PUMA) apoptotic pathways (Benchimol 2001, Pietenpol and Stewart 2002, Vousden and
Lu 2002) (Figure 10). Several p53 target genes have a yet unidentified mechanism of
promoting apoptosis (PIG8, PIDD) (Benchimol 2001). In addition, p53 promotes apoptosis
by activating genes which suppress survival signaling (e.g. IGF-BP3; for insulin-like
growth factor-binding protein 3) and repressing expression of survival-promoting or anti-
apoptotic genes (e.g. IGF-receptor 1, Bcl-2 and survivin) (El-Deiry 1998, Hoffman et al.
2002, Pietenpol and Stewart 2002). Depending on the p53-inducing signal and cell type,
not all apoptotic target genes are necessarily expressed at the same time (Bouvard et al.
2000). The ability to engage various apoptotic routes is likely to be important for tumor
suppression by p53 (Vousden and Lu 2002). The Pro-rich domain is thought to be
important for the apoptotic functions of p53 (Sakamuro et al. 1997). Sin3a interacts with
the Pro-rich domain contributing to the p53-mediated transrepression, which might explain
the importance of the Pro-rich domain to apoptosis (Zilfou et al. 2001).
p53 may launch apoptosis also independently of its ability to regulate transcription by
yet unidentified mechanisms (Vousden 2000), although according to in vivo evidence some
transactivation-deficient p53 mutants are defective in inducing apoptosis (Jimenez et al.
2000, Chao et al. 2000). p53 contributes to shuttling of death receptors to the cell surface
(Bennett et al. 1998) and activates caspase-8 (Ding et al. 2000) by unknown mechanisms
independent of transactivation. Mitochondria and redox regulation may also be involved in
p53-dependent apoptosis (Polyak et al. 1997). A fraction of p53 is localized in the
mitochondria after DNA damage, where p53 can directly induce permeabilization of the
outer mitochondrial membrane by forming complexes with the protective Bcl-XL and Bcl-
2 proteins, resulting in cytochrome c release (Marchenko et al. 2000, Mihara et al. 2003).
There are several proteins which can modulate p53-induced apoptosis. Proteins of the
ASPP family interact with p53 and enhance binding of p53 to apoptotic promoter REs
(Samuels-Lev et al. 2001). JMY co-operates with p300 to enhance the expression of p53
apoptotic targets (Shikama et al. 1999). Interaction of p53 C terminus with DNA helicases,
such as XPD, XPB, BLM (Bloom syndrome), and WRN (Werner syndrome), promotes
apoptosis by yet unidentified means (Robles and Harris 2001). Other proteins affecting
p53-induced apoptosis include LKB1, a tumor suppressor defective in Peutz-Jeghers
syndrome (Karuman et al. 2001), and WT-1, inactivation of which leads to pediatric
kidney cancer (Maheswaran et al. 1995). In addition, induction of cell death by p53 seems
to require the presence of at least one of the other p53 family members p63 or p73 (see
below) (Flores et al. 2002).
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Figure 10. p53 promotes apoptosis by contributing to both death receptor and mitochondrial apoptotic
pathways. p53 induces transcription (arrows) of  death receptors Fas and DR5, inhibitor of survival signaling
IGF-BP3, and apoptosis-promoting Bax, NOXA, p53AIP1, PUMA, and Apaf-1, and represses expression
(blocked lines) of survival-promoting IGF-R1, and anti-apoptotic Bcl-2 and survivin. p53 also activates
caspase 8 by an unknown mechanism (dashed arrow). Additional events are likely to take part in p53-
mediated apoptosis. Adapted from Pietenpol and Stewart 2002.
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Other functions of p53
In addition to Mdm2 and ARF, p53 regulates other target genes to terminate its own
response. p53 induces cyclin G, which negatively regulates accumulation of p53 (Ohtsuka
et al. 2003) apparently by recruiting PP2A (protein phosphatase 2A) to dephosphorylate
Mdm2 Thr218, which thus promotes its ability to mediate p53 degradation (shown for
murine Thr216; Okamoto et al. 2002). p53 target WIP1 (wildtype p53-induced
phosphatase 1) downregulates p38 kinase, leading to decreased Ser46 phosphorylation on
p53 and reduced ability of p53 to transactivate the proapoptotic target p53AIP1 (Takekawa
et al. 2000). Other p53 functions than those involved in cell cycle arrest or apoptosis may
also be crucial for tumor suppressor function of p53 (Vousden and Lu 2002). For example,
p53 activation accelerates degradation of β-catenin, oncogenic activity of which
contributes to a variety of epithelial tumors. KAI1 (kangai 1), a tumor metastasis
suppressor, is induced by p53. p53 stimulates angiogenesis through upregulation of
thrombospondin-1, but it also induces secretion of anti-angiogenic factor GD-AIF (glioma-
derived angiogenesis inhibitory factor). p53 promotes degradation of extracellular matrix
by inducing MMP-2 (type IV collagenase; gelatinase A), but it also induces protease
inhibitor maspin (Vousden and Lu 2002).
p53 regulates limited cell proliferation potential and cellular senescence, which is
another safeguard mechanism to suppress tumorigenesis (Itahana et al. 2001, Donehower
2002). In late passage cultured cells, p53 helps to maintain a nonproliferative state; a
function which is at least partly due to the ability of p53 to upregulate p21Cip1. The p53-
posed proliferation block has to be overcome for cells to immortalize (Itahana et al. 2001).
For human cells, other transforming events are required also. Murine cells are more easily
transformed in culture than human cells, and p53-null murine cells spontaneously
immortalize and transform, as well as have a higher degree of genomic instability than
their wild type (wt) counterparts (Donehower 1996). p53 may also control cell
proliferation under normal circumstances as p53-null mouse embryonal fibroblasts (MEFs)
divide more rapidly, have a shorter cell cycle time, and grow more readily in unfavorable
conditions than MEFs harboring wtp53 (Harvey et al. 1993).
Limited replication potential of human cells is at least partly due to shortening of
telomeres on chromosome ends during each round of DNA replication. It is not clear how
shortening of telomeres under critical length is recognized by the cells, but it has been
suggested to serve as a DNA damage-like signal inducing p53-mediated damage response
(Itahana et al. 2001). hTERT (human telomerase reverse transcriptase), the catalytic
subunit of human telomerase, can prevent shortening of telomeres by synthetisizing
telomere DNA, and thus contribute to increased replication potential of cells (Itahana et al.
2001). p53 downregulates telomerase activity by repressing hTERT expression (Xu et al.
2000) and, possibly, via interaction with hTEP1 (human telomerase-associated protein 1)
(Li et al. 1999).
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Deficiency of p53 function
Sporadic human cancers
Most human cancers seem to have lost p53 function in one way or the other (Vousden
and Lu 2002). Mutations of TP53 itself are found in over half of human tumors (Hollstein
et al. 1991). TP53 is mutated most often in cancers of the lung (70%), the colon (60%), the
ovary (60%), the bladder (60%), and those of the head and neck (60%), but mutated
relatively rarely in leukemia, melanoma and prostate cancers (Soussi 2000). Inactivation of
p53 can also occur by lesions which prevent activation of p53, or by mutations in
downstream mediators of p53 functions (Vousden and Lu 2002). Overexpression of Mdm2
occurs via amplification of HDM2 in 7% of human cancers, with the highest frequency
found in soft tissue sarcomas (20%) (Momand et al. 2000). Mdm2-mediated nuclear
exclusion can be found from tumors of the breast and the colon, and neuroblastoma (Liang
and Clarke 2001, Stommel et al. 1999). In addition, MdmX overexpression may occur in
some tumors (Ramos et al. 2001). Polymorphism of TP53 can also contribute to
tumorigenesis.  Polymorphism at codon 72 results in either a Pro or Arg residue. Arg
replaces one of the five PXXP motifs in the Pro-rich domain and is more susceptible to
degradation mediated by HPV protein E6. Clinically, patients carrying Arg72 p53 are more
susceptible to HPV-associated tumorigenesis (Storey et al. 1998). Interestingly, Arg72-
coding alleles are preferentially mutated and retained in squamous cell tumors arising from
germline heterozygotes coding for both Arg72 and Pro72 p53 (Marin et al. 2000).
Over 90% of tumor-associated mutations of TP53 are point mutations which result in
single amino acid substitutions (Vousden and Lu 2002). Many tumor cells retain their
ability to express mutant p53, and the mutants are often more stable than wtp53. In
addition, loss of heterozygosity occurs frequently to eliminate the wt allele (Greenblatt et
al. 1994). Some of the tumor-associated mutants, e.g. Arg175His, may acquire new
transforming functions which contribute to tumor development (gain-of-function). There
are also p53 mutants which work in a dominant-negative fashion (Sigal and Rotter 2000).
Only 5% of p53 mutations have been found in the regulatory domains (N- and C-terminal
regions), whereas 95% of the mutations occur in the DNA binding core region of p53
(May and May 1999, Prives and Hall 1999, Vousden and Lu 2002). Mutations are most
often located in the conserved regions II-V disturbing DNA contacts or conformation of
the whole domain, and thus resulting in loss of DNA binding ability of p53. Some p53
mutants selectively lose their ability to induce apoptotic targets (Vousden and Lu 2002).
Additionally, different classes of p53 mutants have differential effects on the resistance of
tumor cells to chemotherapy (Blandino et al. 1999).
TP53 mutations can be found in 50% of all skin cancers and in up to 90% of tumors in
DNA repair-deficient XP patients (Giglia-Mari and Sarasin 2003). TP53 mutations in non-
melanoma skin cancers often show a “UV pattern”, i.e. they are mostly C to T transitions
likely to have originated from UV radiation-induced DNA lesions. Sunburn cells in human
skin often harbour p53 mutations (Ziegler et al. 1994). As sunburn is associated with
apoptosis, loss of p53 provides a survival advantage to UV-damaged cells. Clusters of cells
with mutant p53 often found in healthy human skin suggest that mutant p53 can “wait” for
other mutated genes to start the tumorigenic process, as it may itself have a more profound
role later in the tumorigenic process (de Gruijl et al. 2001). Importance of p53 as a target
in UV-induced skin cancers has been verified in mouse models (de Gruijl et al. 2001).
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Li-Fraumeni syndrome
Germline mutations resulting in p53 deficiencies cause a rare hereditary cancer
predisposition called the Li-Fraumeni syndrome. The patients have 50% likelihood of
developing cancer by the age 30, in contrast to 1% in the general population (Donehower
1996). The tumor spectrum includes soft tissue sarcomas and cancers of the bone, the
breast, the brain, and the genito-urinary tract (Malkin 1993). Most Li-Fraumeni-associated
p53 mutations reside in the core domain, but some are found in the oligomerization domain
(Lomax et al. 1997). Li-Fraumeni syndrome-like symptoms can also be caused by
germline mutations on Chk2 (Bell et al. 1999).
Mouse models
Although p53 is unessential for normal development of mice in utero, approximately
20% of female p53-null embryos die during embryogenesis due to a neural tube closure
defect resulting from overgrowth of neural tissue. Fertility is also reduced particularly in
females of the p53 KO mice (Donehower 1996). The most prominent effect of p53
deficiency in mice is severely enhanced tumorigenesis (Donehower et al. 1992, Jacks et al.
1994). The p53-/- mice develop tumors within 4.5 months on average and their
heterozygous littermates by 18 months, as their wt littermates do not develop tumors
before 18 months. Less than 25% of the wt mice have tumors by the age of two years, but
all p53-null mice have tumors by 10 months of age (Donehower 1996).
The tumor spectrum of p53-null mice include lymphomas (60%), soft tissue sarcomas
(over 20%), and brain and lung tumors, but malignant carcinomas are found rarely
(Donehower 1996, Parant and Lozano 2003). In heterozygotes, the tumors observed are
more varied, including lymphomas, soft tissue sarcomas, and osteosarcomas, and the
incidence of carcinomas is increased (Donehower 1996). The genetic background of the
mice affects the tumor spectrum (Parant and Lozano 2003). p53 co-operates with other
cancer-associated genes in mouse models, as mice deficient for both p53 and RB show
accelerated tumorigenesis, and also novel tumor types compared to the parental mice
deficient for either gene (Williams et al. 1994). p53 mutations are found in tumors at a
rather late stage of the malignant development. Interestingly, loss of p53 can inhibit the
initial steps of tumorigenesis, as mice which lack p53 develop fewer papillomas in
response to carcinogen exposure than wt mice (Kemp et al. 1993).
Even though heterozygous p53 mice seem to offer a good model for the Li-Fraumeni
syndrome, the tumors in the p53 KO mice have been speculated not to correspond to the
situation in human cancers particularly well (Donehower 1996). The deletions introduced
to the KO mice do not resemble the point mutations observed in human patients. In
attempts to better mimic the situation in sporadic human cancers, transgenic mice with p53
point mutants have been generated. For example, transgenic mice with oncogenic codon
135 point mutation had accelerated tumorigenesis, but only in the presence of one or both
wild type alleles, suggesting that it functions through inactivating wtp53 (Harvey et al.
1995). Mice heterozygous for Arg172His (corresponds to Arg175His in human) differed
from p53+/- mice in their tumor spectrum with a higher incidence of carcinomas and
metastasizing tumors (Liu et al. 2000).
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p53 family of proteins
After 15 years of solitude, p53 was found to have two family members, p63 and p73
(Kaghad et al. 1997, Yang et al. 1998). These proteins are strikingly conserved, and all
members have an N-terminal TAD, a DNA binding domain, and an oligomerization
domain (Kaghad et al. 1997, Yang et al. 1998) (Figure 11). p63 appears to be the
evolutionary ancestor, and p63 and p73 resemble each other more than p53. p63 and p73
have a C-terminal sterile α-motif (SAM) domain involved in protein-protein interactions,
and a post-SAM domain, which has an inhibitory effect on the transactivation properties of
the proteins. Both p63 and p73 have two promoters, 30-40 kb apart and with unique
regulatory sites, driving transcription of sequences coding for proteins either with or
without the N-terminal TAD (designated as ∆Np63/∆Np73). In addition, alternative
splicing creates variation in the C termini, resulting in at least six major transcripts of both
genes (Yang et al. 2002).
Figure 11. Structure and homology of p53 family of proteins. Upper percentages represent homology
between domains of p53 and other family members, lower persentages homology between p63 and p73.
Modified from Yang et al. 2002.
Full length p63 and p73 can bind to many p53 binding sites, transactivate certain p53
target genes, including p21Cip1, Mdm2, Gadd45, and Bax, and induce cell cycle arrest or
apoptosis (Yang et al. 2002, Benard et al. 2003). p63 and p73 may inhibit transcriptional
activity of p53 by competing of the same binding sites on DNA, but also co-operate in
target gene activation. For example, in MEFs p63 and p73 are needed for p53-induced
apoptosis through their ability to stabilize p53 binding to the apoptotic promoters (Flores et
al. 2002). Interaction of p63 and p73 by mutant p53 impairs their sequence-specific DNA
binding, thereby inhibiting their transcriptional activity (Strano et al. 2002). ∆Np63 or
∆Np73 may inhibit p53 in a dominant-negative fashion through forming heterocomplexes
with p53 (Yang et al. 2002). p53 induces ∆Np73 both on mRNA and protein levels,
forming a possible feedback loop to terminate p53-mediated stress response (Kartasheva et
al. 2002). This may be supported by the ability of ∆Np73 to inhibit Rb, and thus promote
cell proliferation (Stiewe et al. 2003).
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Both Mdm2 and MdmX can bind p63 or p73 forms containing the TAD, inhibit their
transcriptional activities, but not induce their degradation (Irwin and Kaelin 2001, Kadakia
et al. 2001, Calabro et al. 2002). Mdm2 can also induce alterations in the subcellular
localization of p63 and p73, MdmX at least in the localization of p73 (Wang et al. 2001a,
Kadakia et al. 2001). p73 is stabilized by Mdm2 and MdmX (Irwin and Kaelin 2001), but
the stabilization of p63 remains controversial (Kadakia et al. 2001, Calabro et al. 2002).
Instead, viral proteins do not bind and inactivate p63 or p73 as they do for p53 (Irwin and
Kaelin 2001).
Even though members of the p53 family of proteins are structurally and functionally
related, p63 and p73 seem to have at least partly distinct roles from p53. As p53 is essential
for cellular stress responses and tumor suppression, p63 and p73 seem mostly to have cell
type-specific developmental roles (Irwin and Kaelin 2001, Yang et al. 2002, Benard et al.
2003). p63 is constitutively present in the stem cell compartment of many epithelial
tissues, almost entirely as the transcriptionally inactive ∆N form (Yang et al. 2002). p63-
null mice are born without limbs and many epithelial structures, including skin, prostate,
breast, and urithelial tissue (Mills et al. 1999, Yang et al. 1999). p63 is needed for
sustaining viable pool of epithelial stem cells, and p63-null basal cells undergo terminal
differentiation (Yang et al. 2002). p63 is not mutated in human tumors, but is in fact
located in a region (3q27) amplified, rather than lost, in various cancers (Benard et al.
2003). ∆Np63 levels are increased in some squamous cell carcinomas (Hibi et al. 2000),
suggesting a possible role for the inhibition of transcription by p63 in this particular tumor
type.
Even though p73 lies in 1p36, a region with frequent LOH in human cancers, it seems
that p73 is not a tumor suppressor (Benard et al. 2003). No evidence exists of inactivating
p73 mutations in tumors, and p73-null mice do not show increased rate of spontaneous
tumorigenesis (Yang et al. 2002). Instead, they do show neurological, pheromonal and
inflammatory defects. p73 can protect symphatetic neurons from p53-induced apoptosis
during development, as these cells show decreased survival in p73-null mice (Pozniak et
al. 2000). The clinical impact of p73 has been proved so far only for neuroblastoma, where
∆Np73 expression correlates with poor prognosis (Casciano et al. 2002). Oncogenes, such
as E2F1, c-Myc, and E1A, can activate p73 to induce apoptosis independently of p53
(Irwin and Kaelin 2001). A role for p73 is indicated in E2F1-induced apoptosis in
thymocytes, and p73 could be involved in radiation-induced murine T-cell lymphomas
(Irwin and Kaelin 2001, Benard et al. 2003). p73 is DNA damage-responsive, as it is
phosphorylated by c-Abl and stabilized upon IR (Irwin and Kaelin 2001). DNA damage-
dependent acetylation of p73 by p300 selectively enhances the activation of the apoptotic
target genes (Costanzo et al. 2002).
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Aims of the present study
As the cellular response to ionizing radiation is therapeutically relevant, studies
addressing the DNA damage response of p53 have mostly concentrated on IR. Conclusions
from these studies have somewhat inaccurately been applied to create a model in which p53
response to all types of DNA damage is thought to be alike. Accumulating evidence shows,
however, that both the response of p53 and other cellular events induced by IR and UV
radiation are substantially different, most likely due to the different DNA damage types
induced by these stress factors. In addition, it has seldomly been taken into account that p53
response to UV radiation varies depending on the wavelength and the amount of UV
radiation inflicted on the cells.
We wanted to study the basic mechanisms of p53 function and the transcriptional
responses in cells undergoing either a transient cell cycle arrest or apoptosis upon a UV
insult. More specifically, the aims of this thesis research were to:
1. compare the response of p53 to UV radiation at UVB and UVC wavelengths
2. study the dependence of these p53 responses on the magnitude of UV radiation damage
3 .  determine differences between UV-induced p53 and p53 passively accumulated
following proteasome inhibition
4. study the effects of UV radiation on gene expression on a genomic scale
5. to identify new UV-responsive genes
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Materials and methods
Cell culture
The cell lines used in this study are listed in the table below:
Cell line Description and reference             Used in Culture medium
HEL299 human lung fibroblast (CCL-137, ATCC) I DMEM + 10% FCS
NIH3T3 mouse fibroblast (CRL-1658, ATCC) II DMEM + 10% NBCS
p53-/-, mdm2-/- MEF  mouse embryonal fibroblast II DMEM + 10% FCS
   (Montes de Oca Luna et al. 1995)
SaOS-2 osteosarcoma, p53-null (HTB-85, ATCC) II, III DMEM + 15% FCS
WS1 human skin fibroblast (ATCC CRL-1502) I-IV DMEM + 10% FCS + NAA
DMEM, Dulbecco's modified Eagle medium; FCS, fetal calf serum; NBCS, newborn calf serum;
NAA, non-essential amino acids
All cells were maintained in a humidified atmosphere containing 5% CO2 at + 37°C. UV
treatment of cells was carried out with Stratalinker 2400 (Stratagene, La Jolla, CA) with
bulbs emitting either UVC (254 nm) or UVB (312 nm). BioBeam 8000 137Cs γ-ray source
(STS GmbH, Braunschweig, Germany) was used for IR-treatment. Proteasome inhibitors
used were MG132 (Z-Leu-Leu-Leu-CHO; Affiniti Research Products Ltd) and ALLN (N-
Ac-Leu-Leu-norleucinal; Calbiochem). For PI-3-kinase inhibitor treatments the cells were
pre-incubated for 45 min with either LY294002 (Calbiochem) or Wortmannin (Sigma) prior
applying proteasome inhibitors or UVC radiation, and the PI-3-kinase inhibitors were
maintained on the cells for the rest of the incubation periods.
Preparation of cellular extracts
Cell lysates
All the steps were performed in + 4°C. Monolayer cells were washed with Tris-buffered
saline, scraped, and pelleted with brief centrifugation. The pellet was resuspended to buffer
containing 25 mM Tris-HCl pH 8.0, 120 mM NaCl, 0.5 % Nonident P-40, 4 mM NaF, 100
µM Na3VO4, 100 KIU/ml approtinin, 1 mM phenylmethylsulphonyl fluoride (PMSF), and
10 µg/ml leupeptin, incubated on ice for 20 min, and centrifuged (20 000 rcf, 5 min) to
remove cellular debris. Supernatant fraction was collected and stored in - 20°C for further
use.
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Nuclear extracts
Nuclear extracts were prepared in principle as previously described (Andrews and Faller
1991). All the steps were performed in + 4°C. Monolayer cells were washed with
phosphate-buffered saline, scraped, and pelleted with brief centrifugation. The pellet was
resuspended to buffer containing 10 mM Hepes-KOH pH 7.9, 1.5 mM MgCl2, 10 mM KCl,
50 mM NaF, 0.5 mM DTT, 0.2 mM PMSF, 0.1 KIU/ml approtinin, and 100 ng/ml each
leupeptin, E64, and soybean trypsin inhibitor, incubated on ice for 10 min, and vortexed for
10 s. The insoluble fraction was pelleted with brief centrifugation and resuspended to buffer
containing 20 mM Hepes-KOH pH 7.9, 25 % glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2
mM EDTA pH 8.0, 50 mM NaF, 0.5 mM DTT, 0.2 mM PMSF, 0.1 KIU/ml approtinin, and
100 ng/ml each leupeptin, E64, and soybean trypsin inhibitor, incubated on ice for 20 min,
and centrifuged (20 000 rcf, 5 min) to remove cellular debris. Supernatant fraction was
collected and stored in - 70°C for further use.
Methods
A description of the methods, and the reagents used in them, are found in the original
publications (I-IV) as indicated in the table below.
Method             Used and described in
5-BrdUrd incorporation assay I
Flow cytometric analysis I
Immunofluorescence analysis I, II
Immunoprecipitation I, II
Immunoblotting I-III
Northern analysis I, III, IV
Chloramphenicol acetyl transferase (CAT) assay II
Metabolic labeling II
Transient transfections II, III
Construction of mutant expression vectors II, III
Bio-oligo pull-down assay III
Microarray analysis IV
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Results and discussion
UV radiation has a profound role in skin cancer tumorigenesis, mainly due to its ability
to cause mutations which disturb actions of normal cellular maintenance and stress
responses. Functions of the tumor suppressor p53 are central to UV radiation-induced cell
cycle arrest and sunburn apoptosis in skin, but the normal mode of these actions have not
been elucidated in detail. Comparisons with results from UV-damaged skin have proven cell
cultures as relevant models to study UV-induced cytotoxicity (Straface et al. 2001). In this
study, the effects of UV radiation on p53 and adaptive transcriptional responses were
assessed in diploid human fibroblasts. The ability of these cells to adapt to cell culture
conditions with relatively few changes compared to other skin cell types have made them a
commonly used model to study effects of UV radiation on human cells.
The doses of UV radiation used in this study varied between 1 to 5000 J/m2 UVB and 1
to 100 J/m2 UVC. Minimal erythemal dose (MED) in human skin is 200-1000 J/m2 UVB
depending on skin type and pigmentation (Clydesdale et al. 2001). Thus, the doses of UVB
radiation used were physiologically relevant. The UVB radiation dose used as the low dose
(750 J/m2) to study transient cell cycle arrest roughly corresponds to 23 min exposure to
sunlight at noon on a bright midsummer day in Finland (Kolari et al. 1986), or less than 3
minutes on midsummer noon in Italy (Meloni et al. 2000). The high dose of UVB (3500
J/m2) used to study UV radiation-induced apoptosis equals to 1 h 45 min in Finland or 12,5
min in Italy under the corresponding circumstances. In skin, the effects of UV radiation are
complex due to the different cell types and layers the skin contains. Most of sunlight is
restrained to epidermis, which consists mostly of keratinocytes. Yet, 10-15% of UVB from
sunlight penetrates to dermis, where the fibroblasts of the skin are located (Clydesdale et al.
2001). The low and high doses of UVC radiation used in this study (10 and 50 J/m2,
respectively) were chosen on the basis of their ability to provoke similar cellular responses
than the corresponding doses of UVB radiation. This is in accordance with the ability of
UVC to induce approximately 100 times more DNA damage adducts than UVB with the
same amount of energy (Ravanat et al. 2001). The high doses of UV radiation are enough to
induce RNAPII-inhibiting DNA adducts to every gene, taken that they are evenly
distributed throughout the genome (Perdiz et al. 2000). UVC radiation was used as a
simplified model compared to the physiologically more relevant UVB to study the effects of
UV radiation-induced DNA damage on cells.
Dose- and wavelength-dependent cellular responses to UV radiation (I,IV)
When diploid human fibroblasts (cell lines WS1 and HEL299) were inflicted with the
low doses of UV radiation, a transient cell cycle arrest response was induced. DNA
replication declined, as measured by the decreased incorporation of 5-Bromodeoxyuridine
nucleotide to newly synthesized DNA (I, Figure 1A). A rapid arrest was immediately
launched and was detectable by phosphorylation of Chk1 and downregulation of Cdc25A
phosphatase (I, Figure 2), which is in accordance with previous studies (Mailand et al.
2000). A prolonged cell cycle arrest occurred also. This was observed through stabilization
of tumor suppressor p53 followed by upregulation of the CKI inhibitor p21Cip1 both at the
mRNA and the protein level, as measured by western, northern, and microarray expression
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analyses (I, Figures 2,3; IV, Table 1, Figure 6). The changes were mostly recovered by 24 h,
and the cells continued cycling. There was no evident accumulation of cells in G1 and G2
phases of the cell cycle or decrease in S phase cells (before the changes were due to
confluence of the cell cultures by 48 h)(I, Figure 1). Due to the nature of the UV type of
DNA damage, synthesis of DNA is mechanistically inhibited in situ, and at least part of the
lesions have to be removed before synthesis can proceed. The arrest induced by UV
radiation is distinct from e.g. IR-induced cell cycle arrest, where the cells clearly
accumulate to the gap phases of the cell cycle (Bartek and Lukas 2001b). Thus the term
replication arrest seems more appropriate than cell cycle arrest to be used for the arrest
response induced by the low doses of UV radiation.
High doses of UV radiation induced apoptosis in the diploid human fibroblasts.
Phosphorylation of Chk1 and downregulation of Cdc25A were detectable, indicating that a
rapid halting of cell proliferation by DNA damage checkpoints took place also after a fatal
amount of UV damage (I, Figure 2). DNA replication ceased rapidly (before 3 h; I, Figure
1A), probably reflecting both the physical challenge posed by the DNA damage bulges to
DNA replication machinery, and the active, damage-responsive events. p53 accumulation
occurred more slowly in the apoptotic cells than in the transiently arrested cells, and the
levels of p53 protein remained high throughout the follow-up period (48 h)(I, Figures 5,6),
by the end of which most of the cells were apoptotic (I, Figure1). The cells underwent
programmed cell death, detectable by activation of caspase activity and accumulation of
cells undergoing degradation of DNA (cells with sub-G1 DNA content) (I, Figures 1,2).
Interestingly, Cdc25A phosphatase levels were recovered after their initial downregulation
in the apoptotic cells. This may be due to protein production being normalized, allowing
Cdc25A to accumulate again when the initial activation phase by ATR kinase is over.
However, protein synthesis is decreased in cells inflicted with high amounts of RNAPII
blocking agents (Tornaletti and Hanawalt 1999), and it would seem uneconomical for the
cells to consume energy for repairing and expressing an unnecessary gene. The effort to
upregulate Cdc25A phosphatase in cells already determined to undergo apoptosis implies
that it may have a later role in the apoptotic process.
p53 response to UV radiation (I-III)
Already in 1984, p53 was found to be stabilized by UV radiation (Maltzman and Czysyk
1984). Since then, it has become apparent that p53 plays a central role in the cellular
responses provoked by UV radiation, amongst other stress inducers (Prives and Hall 1999,
Vousden and Lu 2002). p53 is essential for efficient protective UV responses in skin, and
loss of its function promotes UV-induced skin tumorigenesis significantly (Ziegler et al.
1994, de Gruijl et al. 2001). Different aspects of p53 regulation by UV radiation have been
extensively studied, but in various cell types, and with various radiation wavelengths and
doses, leaving the results difficult to bring together. Thus, the exact events in p53 regulation
taking place in the different cellular responses to UV radiation have remained elusive. In
this work, the most relevant aspects of p53 regulation in response to UV were studied,
namely the posttranslational modifications, transcriptional activity, and subcellular
localization of p53, as well as its interaction with Mdm2, regulation by PI-3-related kinases,
and the resulting effects to target gene expression.
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UV dose-dependent posttranslational modifications of p53 (I)
Stabilization of p53 by UV radiation is dose-dependent (I, Figures 2,4-6). In cells
undergoing transient cell cycle arrest, p53 accumulated rapidly (accumulation was
detectable already at 2 h, data not shown) and was mostly returned to basal levels by 24 h.
In contrast, in the cells irradiated with the high UV dose, the accumulation occurred more
slowly but eventually gained a higher magnitude than in the arrested cells, persisting up
until the cells underwent apoptosis. The response was similar with corresponding doses of
either UVB or UVC radiation. Even though some influence of oxidative stress cannot be
ruled out, the results indicate that p53 stabilization by UVB is mostly attributable to the
DNA damage inflicted by the radiation.
Further experiments showed that regulation of p53 is significantly different between the
arresting and the apoptotic cellular responses to UV radiation. The N-terminal modifications
of p53 have been suggested to release p53 from Mdm2-mediated degradation and thus
increase stability of p53, but also to promote C-terminal acetylations increasing p53 activity
(Meek 1999, Appella and Anderson 2001). By the use of modification-specific antibodies,
we studied the kinetics of N-terminal phosphorylations of p53 on Ser15, Ser33 and Ser37,
and C-terminal acetylation on Lys382, and the dependency of these modifications on UV
radiation wavelength and dose (I, Figures 4,5). All these modifications occurred by both
UVB and UVC radiation, but the kinetics, measured as the relative saturation degree of p53
molecules by these modifications, varied: Ser37 was phosphorylated more efficiently with
lower doses, Ser15 and Ser33 with intermediate doses, and Lys382 was acetylated relatively
more efficiently with very high doses of both UVB and UVC radiation.
Following the low dose of UV radiation, all the modifications were detectable already as
p53 started to accumulate (I, Figure 5; data not shown). Ser37 phosphorylation was
relatively quickly saturated, followed by Ser15 and Ser33 phosphorylations. The saturation
of Ser15 phosphorylation was more transient, while those of Ser33 and Ser37 fluctuated and
were persistent at 24 h as the cells had re-entered the cell cycle. Acetylation of Lys382 was
modest in the transiently arrested cells. In the cells destined to undergo apoptosis, all the
modifications had an initial burst at 6 h when p53 was not much accumulated yet. After this,
the relative amount of modifications, as compared to the total levels of p53, decreased and
were elevated again by 18 h. Lys382 acetylation was the only modification which decreased
by 24 h in the cells irradiated with the high dose of UV, as the N-terminal phosphorylations
persisted along with the high stabilization of p53 (I, Figure 5). These results significantly
extend information gained from previous studies of p53 modifications in response to
intermediate doses of UV radiation (Sakaguchi et al. 1998, Oda et al. 2000a, Takekawa et
al. 2000,).
The results indicate that in the apoptotic response, the initial activation of p53-modifying
enzymes is rapid, followed by a lag period, after which more activity is present again. ATR
responds to DNA damage very quickly (Bartek and Lukas 2001a,b) and presumably
promotes the rapid modifications of p53 (Prives and Hall 1999, Appella and Anderson
2001). At a later stage in the apoptotic response, either a second phase of ATR kinase
activity follows due to persistent DNA damage or other activating signals, or apoptosis-
associated kinases are responsible for the persistent p53 phosphorylations. Interestingly, this
second phase of enzyme activity does not result in persistent C-terminal acetylation of p53,
even though acetylation of Lys382 is more pronounced with higher doses of UV radiation
(I, Figure 4). Possibly, the enhancement of p53 transcriptional activity by C-terminal
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acetylation has already served its purpose early in the response promoting the apoptotic p53
targets, and is allowed to decrease thereafter. Alternatively, C-terminal Lys382 acetylation
may not favor activity towards the late apoptotic targets, but may be needed for the fine-
tuned activation of targets early in the response. Thus, the second phase of activators would
primarily serve to promote p53 interactions with basal transcription machinery and other
transcription-associated factors via the N-terminal phosphorylations. As reported during the
course of this study, phosphorylations are not essential to p53 activation (Ashcroft et al.
1999, Blattner et al. 1999), but they still frequently occur in different types of p53
responses. They probably supply some advantages for p53 functions by, for example,
ensuring efficient p53 accumulation during the UV response, as reported for the
phosphorylation of Ser15 and Ser33 (Bean and Stark 2001). It would have been interesting
to study whether other p53 modifications occur in the different cellular responses provoked
by UV radiation, especially sumoylation of p53, as well as the phosphorylations on Ser46
and Ser392, which have been linked to p53-induced apoptosis and the UV response,
respectively (Appella and Anderson 2001). Unfortunately, the necessary modification-
specific antibodies were not at hand during the course of this study.
UV dose-dependent regulation of p53-Mdm2 interaction (I)
Mdm2 protein levels were increased in cells transiently arrested by the low dose of UV
radiation. Kinetics of Mdm2 accumulation were slower than that of p53, as expected for the
feedback loop function. To estimate the fractions of p53 bound to Mdm2,
immunoprecipitation analyses were performed (I, Figure 6). The amount of Mdm2-free p53
peaked at 16 h. After this, the interaction between the two proteins increased and led to a
decrease in p53 levels (I, Figure 6). Of the N-terminal p53 phosphorylations studied here,
Ser15 phosphorylation showed the best inverse correlation with p53-Mdm2 interaction in
the arrested cells. In the cells damaged with the high dose of UV radiation, Mdm2 levels
were decreased. Dose-dependent regulation of Mdm2 protein levels in response to UV
radiation have been reported previously (Perry et al. 1993). As Mdm2 is not present during
initiation of the apoptotic response, inhibition of Mdm2 binding by phosphorylating the p53
N terminus seems redundant. Eventually, however, Mdm2 levels were restored, and the
increasing N-terminal p53 phosphorylations by 24h after UV radiation may serve the
purpose of keeping the newly synthetisized Mdm2 unable to bind p53. Alternatively, the N-
terminal phosphorylations may be needed for the enhanced p53 activity to induce the
apoptotic target genes. This may occur via increased interaction of p53 with the
transcriptional apparatus, or via other, yet unidentified mechanisms. In addition, the fraction
of Mdm2-bound p53 was significantly increased by the high dose of UV radiation, even
though Mdm2 protein levels were decreased. This indicates that the increase in p53
accessibility promotes p53-Mdm2 interaction, or that the affinity of Mdm2 towards p53
increases. It would be interesting to study if the putative affinity change is due to altered
modifications on Mdm2.
Regulation of p53 by PI-3-kinases in the UV response (II)
p53 accumulation by DNA damage is dependent on PI-3-kinases (II, Figure 1A; Meek
1999, Appella and Anderson 2001), which most likely reflects the effect of ATM and ATR
on the stabilizing modifications of p53. To find out whether UV radiation induced
posttranslational modifications of p53 in a PI-3-kinase-dependent manner, the modifications
of p53 induced by UV radiation were studied in the absence or presence of chemical PI-3-
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kinase inhibitors (II, Figure 4). The results show that p53 is phosphorylated on Ser15 and
Ser33 in a PI-3-kinase-dependent manner after UV radiation.  Acetylation of p53 to Lys382
by UV radiation was also PI-3-kinase-dependent, probably indirectly via the dependence of
C-terminal acetylations on preceding N-terminal phosphorylations of p53 (Chernov et al.
1998, Lambert et al. 1998, Sakaguchi et al. 1998). We found no changes in the localizations
of p53 and Mdm2 by inhibition of PI-3-kinases, either before or after UV radiation (II,
Figure 2). Some reports have suggested that Ser15 phosphorylation of p53, expected to
occur by ATR after UV insult, or growth factor-dependent phosphorylations of Mdm2 on
Ser166 and Ser186 by PI-3-related kinase Akt affect intracellular localization of these
proteins (Mayo and Donner 2001, Zhang and Xiong 2001, Zhou et al. 2001). As also
conflicting results have been reported (Ashcroft et al. 2002), PI-3-kinases are concluded not
to regulate localization of p53 or Mdm2 under normal cell growth conditions or upon UV
radiation.
Even though inhibition of PI-3-kinases decreases p53 stabilization and posttranslational
modifications induced by UV radiation, induction of p53 target genes was not affected, at
least as measured by induction of target gene p21Cip1 or activation of reporter gene
transcription from a promoter containing multiple high-affinity p53 response elements
(REs) (II, Figure 5). Earlier reports indicate that transcriptional activation of p53 by UV
radiation is independent on the stabilization of the protein, suggesting that an excess of the
protein exists (Lu et al. 1996, Haapajärvi et al. 1997). It is possible that in the cellular
response to UV radiation p53 is saturated on target promoters, at least those with REs
closely resembling the consensus p53 binding sequence. Despite the fact that inhibition of
PI-3-kinases decreases p53 accumulation, there could still be enough active p53 to induce
these targets. Inhibition of PI-3-kinases could affect the ability of p53 to induce
transcription from targets with lower affinity REs.
Dose-dependent induction of p53 target genes by UV radiation (I,IV)
To be able to compare the extent of p53 modifications and Mdm2 interaction with the
cellular effects of p53, the UV-induced changes in expression of selected p53 target genes
was studied by northern analysis of mRNA levels in diploid human fibroblasts. The target
genes were regulated differentially in the two cellular responses, as expected. In the
transiently arrested cells, p21Cip1 mRNA was induced rapidly, correlating to the increase in
its protein levels (I, Figures 2,3; IV, Table 1, Figure 6). Both Mdm2 mRNA and protein
levels were induced slightly later, correlating to increased p53-Mdm2 interaction linked to
the termination of p53 response (I, Figures 3,6). Gadd45 was induced rapidly and transiently
in the arrested cells. The pro-apoptotic p53 target Bax was not induced, and repression of
the anti-apoptotic target Bcl-2 did not take place, indicating that p53-mediated apoptosis
was not induced. In contrast, in the cells undergoing apoptosis, induction of p21Cip1 and
Mdm2 was decreased. Proapoptotic Bax was upregulated, and anti-apoptotic Bcl-2 was
slightly downregulated, indicating that p53-mediated apoptosis was induced. Interestingly,
Gadd45 induction was high and persistent at the mRNA level in the cells destined to
apoptosis (I, Figure 3; IV, Table 2, Figure 6). The function of Gadd45 is unclear, but it is
thought to take part in DNA repair. The powerful induction of Gadd45 in the cells
undergoing apoptosis indicates, however, a role for Gadd45 in UV-induced apoptosis.
Similar results obtained from rat embryo fibroblasts have previously been reported for
Mdm2, p21Cip1 and Bax (Reinke and Lozano 1997). These results confirm that selection of
p53 target genes occurs dose-dependently by UV radiation.
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Redox-regulation of p53 activity (III)
To assess possible selection amongst target gene binding sites in response to genotoxic
insults, the ability of p53 to bind the REs of certain target gene promoters was studied by a
DNA pull-down assay taking advantage of biotinylated oligonucleotides (III). Following
DNA damage (both IR- and UVC-induced), p53 affinity towards Gadd45 RE but not p21Cip1
RE was decreased (III, Figure 2). This effect was found to be dependent on the nucleotide at
positions 3 of the RE, which directly contact the Cys277 residues of p53 tetramers (III,
Figures 3,4). Further results demonstrated that if Cys277 is reduced, p53 maintains strong
binding to REs containing either cytosines (C) or thymines (T) in the positions 3, as p53
with oxidized Cys277 retains high affinity only to REs containing T in these positions (III,
Figure 5). This is attributable to the SH group of Cys277 forming a hydrophobic interaction
with CH3 group of a T, but a hydrogen bond with the NH2-group of a C (Cho et al 1994).
When Cys277 becomes oxidized, the hydrophobic interaction is still possible, but accepting
a hydrogen bond is not. Seemingly, Cys277 of p53 becomes oxidized later in the DNA
damage response, thus leaning the target gene selection towards REs rich for T in the
positions 3. Oxidation of p53 is known to affect its DNA binding through disturbing Zn2+
coordination and correct folding of the protein (Parks et al. 1997, Fojta et al. 1999). A
pattern for p53 DNA binding to target REs may thus consist of three states: in an oxidized
state, when coordination of Zn2+ and proper folding of p53 is lost, no binding to target REs
occurs. When p53 is in a reduced state, correctly folded and binding Zn2+, it binds target
REs without distinction of the chemical bond formed by Cys277. Finally, in a partially
oxidized state, p53 retains Zn2+ coordination but Cys277 is oxidized, and p53 prefers T-rich
REs. Interestingly, TP53 mutation database reports of 64 cases with p53 point mutations at
the amino acid residue 277 (Olivier et al. 2002; database version R7 September 2002). The
most predominating groups of cancer types harbouring this mutation were lung cancer (9
cases) and skin cancer (7 cases), which often originate from external stress capable of
inducing oxidative stress (cigarette smoke and UV radiation, respectively).
The mechanism how Cys277 oxidation occurs is not clear. The minor amounts of
reactive oxygen species caused by IR and UV radiation may be enough to provoke changes
in the redox state of p53. Increased intracellular ROS can cause oxidation of p53, and p53
redox regulation has earlier been shown to be biologically relevant (Meplan et al. 2000).
However, if this is the cause of distinction between p53 REs, one would predict that a
kinetic decrease in binding to Gadd45 RE would increase along with increased UV doses.
As the effect of UV radiation on Gadd45 expression is quite the opposite, it is more likely
that a specific, enzymatic mechanism exists to regulate p53 redox state after genotoxic
insults. Potential proteins to mediate this effect are the redox-sensitive Ref-1 and HIF-1α,
which interact with p53 (Jayaraman et al. 1997, An et al. 1998). Alternatively, the
sustained, high induction of Gadd45 in the apoptotic cells may be maintained by a p53-
independent mechanism.
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UV dose-dependent determination of p53-mediated cellular response
The results so far show that regulation of p53-Mdm2 pathway is significantly different
between the cells undergoing a transient arrest and apoptosis provoked by UV radiation
(Figure 12). The transient arrest response showed a classical feedback loop behaviour of
p53-Mdm2 regulation, while the apoptotic cells lacked accumulation of Mdm2 in response
to p53 stabilization, and subsequently the p53 levels increased further. Despite the persisting
N-terminal phosphorylations of p53, Mdm2 interaction with p53 was relatively increased.
This suggests that the N-terminal phosphorylations on p53 may serve another purpose than
blocking Mdm2 binding to p53, at least in the cells undergoing apoptosis. This could be
promoting p53 interactions with different proteins of transcription machinery (Lambert et
al. 1998, Pise-Masison et al. 1998, Dumaz and Meek 1999, Dornan et al. 2003). Yet, the
impact of PI-3-kinases on p53 activity in the UV response was found to be lesser than
expected. In addition, despite some kinetical differences, the N-terminal phosphorylations
of p53 did not show significant distinction between the dose-dependent cellular responses to
UV radiation compared to p53 levels. On the other hand, the persistence of the C-terminal
acetylation of p53 during the UV response was dose-dependent. As the extent of p53
acetylation decreases late in the apoptotic cells, p53 degradation should take place as the C-
terminal Lys residues are available for ubiquitination. The degradation does not take place,
however, as Mdm2 is not present. It it possible that the following further accumulation of
p53 is a secondary event, if p53 has already performed its transactivating functions while
acetylated. Alternatively, the lack of acetylation of p53 may represent active means to
regulate p53-induced apoptosis. A stepwise accumulation of p53 by UV radiation was
discovered during a more detailed kinetical analysis (data not shown), and p53
accumulation has been reported to occur in an oscillating manner (Lev Bar-Or et al. 2000).
This is thought to occur due to a cyclic nature of p53-Mdm2 feedback loop, which
eventually leads to downregulation of p53 levels. As in the cells undergoing UV-induced
apoptosis the fluctuations cannot be due to actions of Mdm2, deacetylation of p53 may be
one of the active steps leading to further p53 stabilization. Lack of acetylation may direct
p53 interactions with proteins taking part in induction of apoptotic p53 targets or
transcriptional activity-independent p53 functions late in the apoptotic process.
Alternatively, acetylation may directly favor p53 activity towards the early apoptotic
targets, as deacetylation would make p53 transfer its activities towards the late apoptotic
target genes. In addition, redox-regulation contributes to kinetical differences on p53
affinity towards different target gene REs.
Figure 12. (opposite page) Summary of the dose-dependent cellular response to UV radiation in diploid
human fibroblasts. A low dose of UV radiation induces a transient cell cycle arrest (A). An immediate arrest is
induced via Chk1 activation and subsequent degradation of cdc25A. This is followed by a continued cell cycle
arrest and enhanced DNA repair through stabilization and transcriptional activation of p53, leading to
induction of target genes like p21Cip1 and Gadd45. Later in the process, p53 induces Mdm2 to downregulate its
own response, allowing the cells to continue cycling. A high dose of UV radiation induces apoptosis (B). First,
the initial cell cycle arrest is induced as by the low dose of UV radiation. Stabilization and transcriptional
activation of p53 occur slower than in the transiently arrested cells, and are followed by induction of Gadd45
and p21Cip1. Lack of Mdm2 induction allows p53 to accumulate further, leading to induction of the apoptotic
p53 target genes and subsequent initiation of apoptosis. Dotted arrows, attenuated response compared to the
other dose. Dashed arrows, connections / effectors not shown in this work.
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Interestingly, the results indicate a possible affinity change on Mdm2 towards p53 in the
apoptotic cells. Mdm2 may in fact try to sequester p53, but is unsuccessful due to an
imbalance in the levels of the proteins. Interestingly, proness to UV-induced apoptosis in
TCR-deficient cells is associated with lack of activation of Mdm2 transcription (Conforti et
al. 2000), and loss of Mdm2 is enough to induce p53-dependent apoptosis in vivo (de
Rozieres et al. 2000). Furthermore, Mdm2 can be cleaved by caspases in apoptotic cells to
produce a truncated Mdm2 form deficient in the domain required for association with p53
(Chen et al. 1997). The truncated form works in a dominant negative fashion efficiently
inhibiting the activity of full-length Mdm2, resulting in elevated levels of p53 (Alarcon-
Vargas and Ronai 2002). p53 affinity for REs in the apoptotic targets seems to be lower on
average than that for REs of targets inducing cell cycle arrest (Vousden and Lu 2002). This
suggests that as soon as p53 gets accumulated to high enough levels, the transient p53-
mediated arrest response could be overridden by an increased induction of proapoptotic
targets. High accumulation of p53 by downregulation of Mdm2 may thus be a common
mechanism to induce p53-dependent apoptosis, and be a more significant determinant for
the UV-response than the modifications of p53 (Figure 13). Taken together, these results
suggest that both p53 stabilization and activation are regulated in multistep processes to
either guarantee proper termination of the UV-induced p53 response, or allow p53 to
accumulate to high enough levels to initiate apoptosis.
Figure 13. A simplified model of different p53-mediated cellular responses by UV radiation. Initial cell cycle
arrest is launched despite of magnitude of the UV damage (at time 0), following a phase of p53-mediated cell
cycle arrest. If damage repair is succesful, Mdm2 is allowed to accumulate and targets p53 to degradation,
leading to recovery of normal cellular state. If the repair is unsuccesful, p53 is further accumulated activating
also low affinity targets. This leads to initiation of apoptosis which will override the arrest response.
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Regulation of p53-Mdm2 pathway by inhibition of proteasome function (II)
As p53 and Mdm2 are continuously produced, they both accumulate when their
degradation is blocked by inhibition of the proteasome (Momand et al. 2000). This is
thought to occur in the absence of a p53-activating signal, leaving p53 in a latent state. To
study the regulation of p53-Mdm2 pathway by proteasome inhibition, the posttranslational
modifications of p53, the extent of interaction between p53-Mdm2, and p53 transcriptional
activity were studied in the presence and absence of chemical PI-3-kinase inhibitors.
Induction of target gene p21Cip1 was deteceted by northern analysis in cells treated with
proteasome inhibitors, indicating that p53 might be transcriptionally active (II, Figure 5).
This is in contrast with another study reporting that p21Cip1 is not induced by p53
accumulated by proteasome inhibition (Klibanov et al. 2001). The difference may be due to
kinetic changes. In this study, p21Cip1 upregulation occurred at 6 h, whereas Klibanov et al.
reported of 16-h timepoint. p53 was confirmed to be transcriptionally active in
proteasomally inhibited cells by a reporter gene assay. Accumulation and activity of p53 by
proteasomal inhibition were not dependent on PI-3-kinases (II, Figures 1,5). A slight basal
modification of p53 on Ser33 was detected, and, interestingly, it was decreased by inhibition
of PI-3-kinases (II, Figure 4). p53 interaction with Mdm2 in cells treated with proteasome
inhibitors was decreased by inhibition of PI-3-kinases, which was at least in part due to
decreased protein synthesis of Mdm2 (II, Figures 1,6B). The decline in the interaction
occurred also in cells deficient for p53 and in cells treated only with PI-3-kinase inhibitors
(II, Figures 6A,B). Thus, PI-3-kinases regulate the basal levels of Mdm2 independently of
p53.
Lys382 of p53 is not acetylated in diploid human fibroblasts treated with proteasome
inhibitors (II, Figure 4; Ito et al. 2001), indicating that the transcriptional activity of p53
observed in the cells was not due to activating acetylation on p53 C terminus. N-terminal
phosphorylations of p53, which inhibit Mdm2 interaction, are not induced in proteasome-
inhibited cells (II, Figure 4; earlier reports for Ser15 phosphorylation by Shieh et al. 1997
and Siliciano et al. 1997). Yet, a significant pool of p53 free from Mdm2, as well as p53-
free Mdm2, existed in these cells (II, Figure 3). Either p53 accumulation is sufficient to
induce target gene induction of high affinity REs tested here, or proteasome inhibition poses
a stress in itself, which induces some transcriptional activity of p53. As this would occur
without activating C-terminal acetylation on p53, it might be due to other transregulatory
factors promoting the transcriptional activity of p53. Interestingly, preferential T-rich RE
binding of p53 later in the stress response was also detected after proteasome inhibition
(data not shown), indicating active redox regulation of p53 DNA binding. Proteasome
inhibition triggers heat shock response via HSF1 (heat shock factor 1)-mediated induction of
Hsp’s (Pirkkala et al. 2000). p53 interacts with Hsp70 and Hsp90 chaperones, which can
affect conformation of p53 (Zylicz et al. 2001). It is tempting to speculate that heat shock-
associated factors could take part in the regulation of p53 activity in response to proteasome
inhibition.
Proteasome inhibition caused translocation of both p53 and Mdm2 to the nucleoli of the
cells, as observed by immunofluorescence microscopy (II, Figures 2A,B). This effect could
be blocked by PI-3-kinase inhibitors (II, Figures 2A,B). A small fraction of p53 has been
shown to localize to the nucleoli overlapping rRNA transcription sites (Rubbi and Milner
2000), suggesting that p53 might contribute to rRNA synthesis. The nucleolar localization
of p53 upon proteasome inhibition and its dependence on PI-3-kinases were, however,
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independent of the ability of p53 to bind DNA (II, Figure 2D) and thus not attributable to
the transactivation function of p53. ARF, although capable of translocating Mdm2 into
nucleoli (Weber et al. 1999), was not required for Mdm2 translocation after proteasome
inhibition, nor was p53, as the translocation effect was observed also in cells deficient for
ARF or p53 (II, Figure 2C). Phosphorylation of Mdm2 on Ser166 and Ser186 by Akt has
been described to regulate Mdm2 translocation (Mayo and Donner 2001, Zhou et al. 2001).
Therefore, it was tested whether mutations of these sites would hinder nucleolar
translocation of Mdm2 by proteasome inhibition. Mutation of these sites, or mutation of any
other known or putative PI-3-kinase phosphorylation site on Mdm2, did not inhibit
translocation of Mdm2 to nucleoli upon inhibition of the proteasome function (II, Figure
6C). Thus, direct modifications of Mdm2 or p53 by PI-3-kinases are not responsible for the
effect. In addition to p53 and Mdm2, several proteins have been found to localize to
nucleoli following proteasome inhibition, including Hsp70, PML and SUMO-1 (Mattsson et
al. 2001). Interactions between Mdm2 and both Hsp70 and PML after proteasome inhibition
have been found (Kurki S et al., unpublished results), suggesting that these factors may
bridge the nucleolar localization of Mdm2 and possibly p53. It is also possible that
nucleolar translocation of stress-responsive proteins represents a common, yet functionally
unknown, response mechanism in cells which are eventually dying due to proteasome
dysfunction.
Large scale transcriptional changes in UV radiation-induced replication
arrest and apoptosis (IV)
Recent microarray studies of UVB responses in keratinocytes and melanocytes (Li et al.
2001, Valery et al. 2001, Sesto et al. 2002, Takao et al. 2002) have gained interesting
insights on genes responsive to low insults of UV radiation. These surveys did not assess
effects of apoptosis-inducing doses of UV damage, however. To study how UV-induced
arrest and apoptosis differ on transcriptional level, the study I, indicating that dose-
dependent cellular responses to UV radiation are highly distinct, was expanded to analyze
transcriptional changes on a large scale. As the primary interest was responses provoked by
UV radiation-induced DNA damage, UVC wavelength was used as a simplified model to
induce transient replication arrest or apoptosis in the fibroblasts. Levels of over 12000
transcripts were screened by microarray analysis for changes induced by UV radiation.
Based on analysis of the experimental variation between the samples (IV, Figure 1), a cut-
off value for the significant changes in transcript abundance was set to 3-fold (a proportion
of false positives less than 5%). 460 transcripts were regulated significantly by UV
radiation, of which 89% were downregulated (68 transcripts by the low and 361 transcripts
by the high dose)(IV, Figure 2). Only 5% of the significantly regulated genes were common
to both the transient arrest and apoptosis induced by UV radiation (10% of the induced and
4% of the repressed transcripts). In addition, transcripts undergoing significant regulation
were not regulated even modestly by the other dose, indicating that the vast majority of the
UV-regulated targets were highly specific for either dose (IV, Figure 4). This demonstrates
that dose-dependent induction of transient replication arrest and apoptosis by UV radiation-
induced DNA damage are highly distinct responses at the transcriptional level.
The significantly regulated transcripts in the cells treated with the low dose of UV
radiation had transient changes in their expression patterns, followed by a recovery by 24 h
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(IV, Figure 3). The cells treated with the high dose underwent slower, but more persistent,
changes in transcript levels (IV, Figure 3). These results correlate well with the kinetic
differences detected in the cellular responses (I). Fast and transient induction of transcripts
by the low dose of UVC radiation may result from fewer damaged sites undergoing repair,
enabling faster recovery from transcriptional repression. The high dose of UVC radiation
represses significantly more genes from more functional groups than the low dose,
indicating a more general downregulation of transcription (IV, Figure 2). This is not
surprising, as the high dose is sufficient to produce RNAPII-inhibiting DNA bulks to every
gene of the genome (Perdiz et al. 2000). The data support the idea that UV radiation-
induced DNA damage induces prominent inhibition of transcription, which is mostly
attributable to inhibition of RNAPII (Tornaletti and Hanawalt 1999, Ravanat 2001). Over
90% of transcripts detected in the array were, however, not significantly regulated by UVC.
In addition, if the damage is assumed to distribute randomly throughout the genome, all
genes repressed by the low dose should also be repressed by the high dose. This was not the
case, however, indicating that in at least transiently arrested cells also target gene selective
repression takes place.
Several interesting genes, which may have an impact on the UV response, were found to
be regulated in the large scale assay (IV, Tables 1,2). In addition to p21Cip1, several cell
cycle-associated genes were induced and none were repressed by the low dose of UV
radiation. These factors, e.g. TOB1 and the p53 target BTG2, most likely contribute to the
transient proliferation arrest response, ensuring time for damage repair. Several stress
response factors were also upregulated, including the major heat shock proteins Hsp70 1A
and 1B. These factors work as chaperones in stress involving protein misfolding, and they
are known to respond to UVB (Park et al. 2000, Kwon et al. 2002). UVC does not induce
significant amounts of protein damage (Tyrrell 1994), but chaperones may be needed to
keep NER proteins properly folded, as found in E. coli (Zou et al. 1998). Subunit 4 (p52) of
TFIIH is directly involved in transcription and NER (Marinoni et al. 1997), and was
identified as a novel target induced by the low dose of UVC (IV). Other NER factors which
were slightly induced specifically in cells undergoing transient arrest represented GGR
proteins p48/DDB2 and XPC, known to be upregulated by UV radiation (Hwang et al.
1999, Adimoolam and Ford 2002). The transcript of member O of the histone H2A family
was induced by the low dose of UV radiation, implying that it may have a role in NER
and/or histone remodeling in the UV response.
Transcriptional response in the cells undergoing apoptosis did not include prominent
upregulation of proapoptotic genes. Many apoptotic initiation and effector cascades do not
require de novo protein synthesis, but function mainly through modulation of existing pools
of protein, e.g. by translocation and proteolysis (Gupta 2001, Leist and Jäättelä 2001). Thus
it can be argued that transcriptional events are not the main mode of regulation in UVC
radiation-induced apoptosis. An exception was NOXA, a proapoptotic p53 target gene (Oda
et al. 2000b), which was found to be the most highly induced gene by the high UV dose
(IV, Table 2). Another p53 target upregulated in the apoptotic response was ATF3,
significance of which for UV-induced apoptosis remains to be elucidated. Three histones
were upregulated kinetically late in the apoptotic response, indicating that they may have
specific roles in apoptosis, e.g. changing the composition of nucleosomes to modify DNA
accessibility to DNA degrading enzymes. Transcription was affected by the downregulation
of several basal and sequence-specific transcription factors in the apoptotic response.
Interestingly, these include Id-family of transcriptional repressors (inhibitors of DN A
binding; Id1, 2, 3), which negatively regulate cell cycle inhibition by downregulating
transcription of CKI p16INK4a (Id1; Ohtani et al. 2001) and overriding functions of Rb (Id2;
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Iavarone et al. 1994, Lasorella et al. 1996). In addition, both subunits of the NF-Y (nuclear
transcription factor Y) transcription factor were downregulated. NF-Y upregulates
transcription of several damage response and cell cycle-promoting genes, such as hsp70,
E2F1, cyclin A and cyclin B1 (Mantovani 1998). Downregulation of the Id-family and NF-
Y may block survival-promoting transcription, and prevent the cells from entering the cell
cycle erroneously in the apoptotic response. Mitosis is hampered after the high dose UV
insult through downregulation of mitotic cyclins A2 and B1. Interestingly, cyclin D (D1-3)
is not downregulated in the apoptotic response. This is probably attributable to the efficient
G1/S arrest already induced through Cdc25A- and p53-mediated events, and
downregulation of cyclin D at protein level (I, Figure 2; Bartek and Lukas 2001a, Agami
and Bernards 2002).
Fibroblasts participate in UV-induced inflammation in skin (Clydesdale et al. 2001). The
major inflammatory factors induced by both low and high doses of UV damage were IL-11
(interleukin 11) and ISG15. IL-11 is a secreted cytokine able inhibit apoptosis and
proliferation, stimulate tissue fibrosis, regulate B cell functions, and to inhibit macrophage
cytokine production (Leng and Elias 1997). IL-11 can reduce apoptosis in UVB-irradiated
mouse skin (Scordi et al. 1999). ISG15 is a secreted ubiquitin-like covalent modifier
protein, which has immunomodulatory characteristics (D’Cunha et al. 1996). Consequences
of ISG15 conjugation are speculated to alter biological activities of proteins but remain
unclear. Other aspects of intercellular signaling differed between the arrested and the
apoptotic fibroblasts. By inducing PLAB (placental bone morphogenetic protein), the
arrested cells may promote wound healing and inflammation (Fairlie et al. 1999). They may
also activate integrin-mediated migration, attachment, and angiogenesis via induction of
Ephrin B (Huynh-Do et al. 2002), and loosen cell-cell interactions by downregulation of N-
cadherin (Wang et al. 1998). Apoptotic cells mostly suppress intercellular growth factor
signaling by downregulating transcripts of the TGF-β (transforming growth factor β) and
several cytokine pathways. In addition, other events most likely able to affect their local
environment are downregulation of several angiogenic transcripts and induction of
proteolytic genes, such as MMP-3 which contributes to breakdown of collagen matrix in
photodamaged skin (Wlaschek et al. 2001).
Even though changes in transcript abundance by UV radiation-induced DNA damage are
thought to occur mainly due to changes in transcription, alterations in mRNA stability,
resulting from both direct UV radiation-induced molecular damage and specific regulatory
events, may affect the results. Eventually however, the most important determinant for the
cellular response is whether the changes detected in mRNA levels are translated into altered
protein levels as well. This poses a challenge for future studies. Remarkably many of the
genes upregulated by UV radiation coded for proteins with unknown functions, especially in
the transient arrest response. It will be interesting to determine if some (or even most) of
these genes have a role in the protective DNA damage checkpoint functions, and whether
their transcription is p53-dependent.
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Concluding remarks
Deprivation of the ozone layer and changes in life styles increase the amount of UV
radiation we are exposed to, which, undoubtedly, will further increase the skin cancer rate in
the future. Tumor suppressor p53 is an essential fighter in the battle against skin cancer, as
well as against almost every other type of human cancer. Despite 20 years of determined
research on p53, the exact molecular mechanisms of its functions are not clear. This thesis
work posed questions about the mechanisms of tumor suppressor p53 function and
transcriptional regulation in the cellular responses to UV radiation.
p53 takes actively part in two types of cellular responses induced by UV radiation:
transient replication arrest and apoptosis. The choice of response is mainly determined by
the amount of DNA damage induced by UVB and UVC radiation, as are the transcriptional
targets regulated by p53 to enforce the cellular outcome. The extent of inhibition by Mdm2
seems to determine between the different p53-mediated cellular responses. The results also
indicate a role for redox regulation and acetylation of p53 in the decision whether a cell is to
die due to a UV insult. In contrast, phosphorylation and role of PI-3-kinases in the
regulation of p53 may have a lesser impact than expected in the dose-dependent cellular UV
response.
Proteasome inhibition is thought to induce passive accumulation of p53 and Mdm2. The
results presented here suggest that some parts of p53 activity might be inducible by
proteasome inhibitors, potentiating the existing ideas of using proteasome inhibitors as
cytotoxic drugs in cancer treatment. In addition, by using inhibitors of PI-3-kinases, these
enzymes were found to mediate basal expression of Mdm2. The combination of the drugs
revealed an earlier unidentified intracellular translocation event, significance of which for
normal cell function, as well as apoptosis induced by these drugs, will be determined in
future experiments.
Transcriptional changes in cells undergoing either UV radiation-induced cell cycle arrest
or apoptosis are clearly different. These changes provide effectors for a UV-damaged cell to
either survive from the insult or die, if necessary. Transcriptional changes also provide tools
for a cell to communicate with its surroundings: to influence the damage response of
neighbouring cells and to receive incoming signals in return. The results implicate that
fibroblasts take part in the inflammatory and angiogenic responses to UV radiation, in
concert with other cell types in skin. Several functionally uncharacterized genes were
identified as UV-responsive in this study. Products of some of these genes are likely to
participate in the cellular defense responses to UV radiation. Future work will elucidate
whether some of these genes also regulate cell cycle arrest and apoptosis, and even have the
potential to contribute to tumorigenesis.
During the last 20 years – the “life” of p53 – cancer research has come a long way. We
know now that cancer occurs when series of things go wrong on (mostly) genetic level, and
have identified what many of these events are. The sequencing of human genome has
narrowed down the group of remaining suspects, and eventually all genes contributing to
tumorigenesis will be known. What remains to be achieved, is to elucidate the exact
molecular mechanisms of function of these factors, before their targeting can efficiently and
safely be used in cancer therapeutics.
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